

AUTHOR INDEX

- Abboud, P., 326, 1792
 Abella, S., 546
 Aberg, J. A., 124
 Abraham, O. C., 546
 Abter, E. L., e100
 Acar, J., S156
 Accordini, A., e143
 Acheson, D. W. K., 1517
 Adachi, J. A., 1706
 Adle-Biasette, H., 1371
 Adler-Klein, D., 352
 Adult and Adolescent Spectrum
 of HIV Disease Project, 794
 Agematsu, K., 1399, 1408
 Agüero-Rosenfeld, M. E., 862
 Ahmad, H., e100
 Ahn, K.-M., 1463
 AIDS Clinical Trials Group, 1615
 Akgün, Y., e59
 Akiyama, H., 1325
 Al-Abdely, H., 50
 Alagaratnam, M., 1691
 Alaimo, C., 1126
 Alam, A., 884
 Alangaden, G. J., 313, 546
 Al-Awar, G., 820
 Alberici, E., 638
 Alberio, L., 1338
 Albert, M. J., 884
 Allegra, L., 1281
 Allen, J. E., 1378
 Allos, B. M., 1201
 Almirante, B., 1024
 Almuneeff, M. A., 220
 Alonso, P., 970
 al-Ramadi, B., e87
 Alvarez-Olmos, M. I., 1567
 Amabile-Cuevas, C. F., S30
 Anaissie, E. J., 1713
 Anargyrou, K., 1718
 Andersson, B. S., e94
 Andre, M., 44
 Andremon, A., 1393
 Andres, A., 17
 Andrews, M.-M., 1470
 Anekthananon, T., 483
 Añel, R. M. L., e131
 Anguita, M. L., 17
 Anis, A. H., 1685
 Anstead, G. M., 295
 Antique, J., 1117
 Aplasca de los Reyes, M. R., 1313
 Apolinario, I. S., 808
 Appelbaum, P. C., 1463
 Apperley, J. F., 413
 Arashima, Y., 989
 Arend, S. M., 323
 Arevalo, J., 808
 Arista, S., 1126
 Ariza, J., 1024
 Arjoso, S., 1039
 Arlet, G., 1776
 Armstrong, W. S., 766
 Arrowood, M. J., 1010
 Artola, V., e105
 Arvilommi, H., 1577
 Asaad, R., 1487
 Ascioğlu, S., 1713
 Ashford, D. A., e78
 Ashkin, D., 323, 515
 Assmann, S. F., 116
 Aswapokee, N., 1463
 Attorri, S., 1511
 Auletta, L. J., 9
 Avery, R. K., 1656
 Azoulay, E., 30
 Babcock, H. M., 1373
 Babl, F. E., 1155
 Baccus-Taylor, G., 890
 Bachmann, S., 842
 Backenroth, R., 1502
 Baddley, J. W., 1319
 Baddour, L. M., e17
 Badri, S. M., 826
 Baer, E. T., 991
 Bahrani, A., 1231
 Bailey, A. M., e151
 Baker, C. J., 1018
 Baker, D. K., 36
 Baker, J., 1784
 Bakken, J. S., 862
 Balasubramanyam, A., 153
 Baldwin, M. S., 1010
 Ball, P., S72
 Ball, R., 1273
 Ballas, K., e111
 Ballet, J. J., 1792
 Baltimore, R. S., 220
 Baluch, M., 862
 Bamberger, D. M., 1215
 Banerjee, D., 396
 Bange, E.-C., 1648
 Bani-Sadr, F., 963
 Bañuls, A.-L., 302
 Baquero, F., 1298
 Baran, J., Jr., 1381
 Barboteu, M., 30
 Barlow, G., 728
 Barnett, E. D., 1004
 Baron, E. J., 605
 Barry, M., 1470
 Barth, A., S133
 Bartlett, S., 1623
 Barton, T. D., 391
 Barza, M., 1
 Basara, N., e1
 Basgoz, N., 130
 Bates, D. W., 686
 Baughn, R. E., 534
 Baynes, R., 546
 Beach, M., S114
 Beato, J. L., 506
 Beatrice, S. T., 1227
 Becerril, B., 587
 Becker, K., 1643
 Becker, S., 1615
 Beguinot, L., 1494
 Beinker, N., 1487
 Belkengren, R. P., 694
 Bell, J., S114
 Belongia, E. A., 1434
 Benčina, D., e31
 Benepal, T., 469
 Ben-Haim, M., 822
 Bennish, M. L., 331
 Benoit, C., 1776
 Benson, C. A., 815, 1615
 Bentley, G., 313
 Bentley, M., 476
 Beqaj, S., 1657
 Berbers, G. A. M., 2
 Berkelhamer, S., 1090
 Bernabeu, M., 587
 Berning, S. E., 643
 Bersoff-Matcha, S. J., 124
 Bethell, D. B., 243
 Beveridge, R. A., 381
 Bevilacqua, S., 1494
 Bica, L., 492
 Bier, J. W., 1010
 Biliková, E., 1110
 Bilker, W. B., 1162
 Binkin, N. J., 373
 Bischoff, M., e1
 Bishara, J., e176
 Bitnun, A., 1674
 Blaser, M. J., 295
 Blasi, F., 1281
 Blau, I. W., e1
 Blockmans, D., 191
 Blot, F., e92
 Blumberg, E. A., 307
 Blumer, J. L., 381
 Bobbaers, H., 191
 Bodey, G. P., e145
 Boeckh, M., 214, 321
 Bogdan, C., 302
 Bonsu, B. K., 566
 Bordigoni, P., 1290
 Borkowsky, W., 801
 Bornstain, C., 30
 Borock, E., 1090
 Borsa-Lebas, F., 1792
 Bossi, C., e143
 Böttger, E. C., 1648
 Boudjema, H., 830
 Braconier, J.H., 1523
 Braggion, C., e15
 Brasseur, P., 1792
 Braun, M. M., 1273
 Brazier, S., 975
 Breiman, R. F., 283
 Breukels, M. A., 1700
 Bridges, C. B., 1784
 Brinkman, K., 1095
 Britigan, B. E., 255
 Broadhead, R., 1496
 Brown, B. A., 1547, 1648
 Brown, C., 890
 Brown, P., 1221
 Brozena, S. C., 307
 Brugieres, P., 1371
 Brun-Buisson, C., e92, 877
 Bruneel, E., 1133
 Brunori, M., 1414
 Burke, G., 662
 Burman, W. J., 836
 Bush, K., 1085
 Bybel, M., 170
 Caballero-Granado, E. J., 587
 Cabrera, C. E., 855
 Cacoub, P., 1207
 Cadranet, J.-F., 830
 Calderon, M., 808
 Cammarata, S. K., 402
 Canale, S., e154
 Cañas, C., 1024
 Canas, L. C., 1639
 Canton, P., 1494
 Cantón, R., S94, 1298
 Canzonieri, V., 1100
 Caramico, L., e111
 Carbone, A., 1100
 Carling, P. C., 1519
 Carlos, C. C., 1463
 Carlson, C., 983
 Carmeli, Y., 1055
 Carmoi, T., 991
 Caro, P., 17
 Caron, C., 830
 Caron, F., 326, 1792
 Carosi, G., 1063
 Carret, A.-S., 1290
 Casadevall, A., 670
 Casanova, A., 1024
 Cascio, A., 1126
 Casellas, J.-M., S94
 Cassels, L., 546
 Castagnola, E., 1532
 Cazier, A., 830
 Cazzola, G., e15
 Celum, C. L., 611
 Chalasani, G., 546
 Chambers, H. F., 521
 Champlin, R. E., 871
 Chan, E. D., 1506
 Chan, P. K. S., 1376
 Chan, R. M. T., 701
 Chandenier, J., e154
 Chandrasekar, P. H., 313, 320,
 546
 Chang, C. H., 1657
 Chang, Y. J., 1104
 Chapnick, E. K., e100
 Chappell, C. L., 1516
 Chariyalertsak, S., 955
 Charrois, A., 297
 Chaturvedi, V., 1034
 Chau, T. T. H., 243

- Chavez, V. M., 808
 Chen, G., 534
 Chen, K., 170
 Chen, M.-Y., 1361
 Chen, Q., 1325
 Cheng, A. F., 1376
 Cheng, V. C. C., 701, 846
 Cherian, T., 1463
 Cherry, T. A., 643
 Chertow, G. M., 686
 Chesney, M., 476
 Cheung, J. L. K., 1376
 Chevalier, B., 991
 Chevet, S., 30
 Chiphangwi, J. D., 1496
 Chiu, C.-H., 520, 1463
 Chiwakata, C. B., 144
 Choi, E.-H., 1423
 Chongthaleong, A., 1463
 Choo, P. W., 140
 Chow, A. W., 381
 Chowdhry, T. K., 1487
 Christiansen, E., 1373
 Chuang, E. L., 214
 Ciancio, G., 662
 Cisneros, J. M., 587
 Ciufolini, M. G., 1241
 Claiborne, C. V., 502
 Clarridge, J. E., III, 1511
 Cloud, G., 1215
 Cockerill, F. R., III, 1540
 Cohen, D. E., 1756
 Cohen, M. S., 255
 Cohen, Y., e176
 Cohn, D. L., 623
 Cohn, W. E., e120
 Colby, T. V., 1448
 Coldsmith, E. E., 938
 Collier, A. C., 116
 Collis, T. K., 391, 611
 Colson, A. E., 140
 Comissiong, E., 890
 Connick, E., 1623
 Connor, B. A., 396
 Coons, S. J., e47
 Corcoran, C., 130
 Corey, G. R., 647, 975
 Corey, L., 214
 Corredoira, J. M., 1024
 Corresponding Group, 1133
 Corvatta, L., 1414
 Couch, L. A., 1547
 Coutarel, P., 830
 Craft, J. C., 1798
 Craig, F. E., 295
 Crane, L., 1221
 Craven, D. E., 1249
 Crawford, S., e140
 Crippa, F., 214
 Cron, S. G., 1516
 Cuberos, L., 587
 Culotta, A., 808
 Cumsille, F., 855
 Cunha, B. A., 671
 Cunningham, C. K., 801
 Currier, J. S., 1615
 Cusi, M. G., 1241
 Cu-Uvin, S., 476
 Czachor, J. S., e53
 D'Agata, E. M. C., 23
 D'Agostino, R. B., 130
 Dalhoff, A., S16, S22
 Dallabetta, G., 1313
 Daniels, N., 890
 Danilovitch, M., 373
 Danis, M., e154, 1133
 Danner, S. A., e81
 Dansey, R., 546
 D'Aquila, R. T., 774
 Darmon, M., 30
 Dasbach, E. J., 686
 da Silva, A. J., 1010
 Davey, P., 728
 Davidson, R., 1487
 Davis, B., 130
 Davis, L. E., 979
 Davis, S., 236
 Davis, T., 1487
 Day, N. P. J., 243
 De Boeck, K., e62
 De Caestecker, J., 191
 De Clercq, E., e62
 De Dobbeleer, G., e9
 Deeter, R. G., 1657
 De Guzman, A. M., 1784
 Dekumyoy, P., e154
 de la Brassine, M., e9
 Delacour, T., 830
 Delamare, C., 297
 Delangle, M. H., 162
 Delate, T., e47
 Delgado, J., 633
 de Maubeuge, J., e9
 Dembry, L. M., 220
 de Melker, H. E., 2
 de Metz, J., e81
 Denic, L., 1393
 Denis, F., 197
 Denning, E., 623
 de Oliveira Macêdo, V., 1304
 Derdelinckx, L., e9
 Desachy, A., 197
 de Tomas, E., 506
 De Witt, C. C., 1639
 Dhar, R., 492
 Diaz, P. S., 694
 Dick, J. D., e36
 Didier, J., 30
 Diekema, D. J., S114
 Dietrich, M., 144
 di Gennaro, G., 1100
 Dik, H., 323
 Di Martino, V., 830
 Dionisio, D., 1241
 DiPersio, J. R., 1562
 DiPersio, L. P., 1562
 Dismukes, W. E., 255, 518
 Dlugos, D. J., 173
 Dodek, P. M., 1685
 Dodson, D. R., 1010
 Doern, G. V., S81
 Dolan, D. M., 1639
 Dolan, M. J., 1639
 Doney, A., 1034
 Dorvaux, V., 1494
 Douard, M. C., 1776
 Doucette, K., 1500
 Dovč, P., e31
 Dowdy, L., 662
 Dowell, S. F., 824
 Drachenberg, C., 167
 Duim, B., e97
 Duliege, A. M., 801
 Dumler, J. S., 862
 Dumot, J., 1656
 Dumouchel, P., 830
 Dunbar, S., 1511
 Dung, N. M., 243
 Dung, N. T., e78
 Duong, N. M., e78
 DuPont, H., 331, 1706
 Dutta, D. K., 884
 Dworkin, H., 1657
 Dworkin, M. S., 794
 Dwyer, A. P., 1506
 Dylewski, J., 1112
 Eberhard, M. L., 1010, 1378
 Ebright, J. R., e90
 Eby, G. A., 1520
 Edelman, L., 667
 Edelstein, P. H., 1162
 Edlund, C., 1384
 Edmond, M. B., 1538
 Edwards, J. E., Jr., 76, 518, 1110
 Edwards, K. M., 847, 1698
 Egger, M., 995
 Elgart, L., 1366
 Elizaga, J., 413
 Ellis, M. E., 50, e87
 El-Sadr, W. M., 623
 Elsen, C., 1090
 Elta, G., 983
 Elting, L., 871
 Embil, J. M., 636, 1500
 Emery, K. W., 708
 Emery, V. C., 1357
 Englund, J., 1090
 Enting, R. H., 1095
 Epstein, D., 559
 Erdman, D. D., 694
 Ericsson, C. D., 1706
 Eriksson, B. K. G., e24
 Escobar, H., 1298
 Esmon, C. T., 1338
 Espaze, E., 162
 Esperti, F., 1241
 Esposito, S., 1281
 Esteve, A., 159
 Estey, E., 539
 Etienne, J., 1440
 Etienne, M., 326
 Fabregat, J., 1024
 Faccini, M., e143
 Fang, C.-T., 1361
 Faris-Young, S., 167
 Farr, B. M., 1249
 Farrar, J., 204
 Farrel, P. A., 220
 Fauci, A. S., 675
 Fauser, A. A., e1
 Favenec, L., 1792
 Feddersen, R. M., 300
 Feenstra, L., e62
 Feinberg, J., 1615
 Feld, R., 381
 Fennelly, K., 1506
 Fenton, T., 801
 Fernandez, M., 1018
 Ferraz, V., 289
 Fichtenbaum, C., 1615
 Fierer, J., 519
 File, T. M., Jr., 1562
 Filler, S. G., 518
 Fine, A., 277, 1784
 Finkel, M. F., 1434
 Fisher, D., e102
 Fishman, N. O., 1162
 Fisman, D. N., 419
 Fitzgerald, T., 1657
 Flagg, S. D., 1104
 Flanagan, T. P., 116
 Fleer, A., e97
 Fleisch, F., 581
 Fleisher, A. S., 502
 Fleisher, G. R., 1004
 Fleming, T., 476
 Fluit, A. C., S81
 Flynn, P. M., 36, 1456
 Foley, K. M., 1331
 Fonquernie, L., 297
 Ford, G., 842
 Ford-Jones, E. L., 1674
 Forgacs, P., 179
 Forman, M. S., e13
 Forrest, D. M., 1685
 Forward, K. R., S104
 Foster, C. L., 367
 Fournier, P.-E., 1440
 Fowler, V. G., Jr., 647
 Francis, D., 801
 Franco, C., 1103
 François, B., 197
 Fraser, V. J., 1331
 Frederiksen, W., 987
 Freedberg, K. A., 783
 Freedman, D. O., 757
 Freidberg, S. R., 179
 French, M. A., 325
 French, P., 660
 Fridkin, S. K., 108
 Friedlaender, M. M., 1502
 Froeschle, J. E., 170
 Frottier, J., 297
 Fujita, K., e22
 Fukuda, K., 1784
 Fullem, A., 476
 Gabay, B., e176
 Gachot, B., 1133
 Gaillon, S., 1393
 Gajewski, J., 871
 Gales, A. C., S104, S146
 Gamble, J., 243
 Gantz, N. M., 938
 Garcia-Diaz, J. B., e166

- Gargala, G., 1792
Garman, R. L., 824
Gartside, I. B., 243
Gassin, M., 963
Gastinne, H., 197
Gaur, A. H., 1456
Gazzard, B. G., 469
Geddie, Y. A., 1639
Geelen, S. P. M., e97
Geffray, L., 1207
Gennings, C., 1538
George, J., 170
Gerber, S. I., 694
Gershman, K., e151
Gessain, A., 510
Gessner, B. D., 1039
Geyer, C. A., 179
Ghosh, S., 539
Giamarellos-Bourboulis, E. J., 1718
Giamarellou, H., 1718
Gibbard, W. B., 1637
Gigliotti, F., 855
Gill, J., 469
Gilliland, K. K., 539
Gilman, R. H., 808
Gilroy, C. B., 995
Giralt, S., 871
Girard, W. M., 1547
Giry, P., 1393
Gitlin, S. D., 983
Glatt, A. E., 752
Glauser, M., 1532
Glover, L., 1784
Gluckman, S. J., 505
Golden, M. P., 1366
Goldie, S. J., 419, 783
Goldman, J. M., 413
Goldstein, J., 1657
Goldstein, L. J., 970
Gomes, D. R. J., 686
Gomes Paes, M., 1304
Gómez-Mampaso, E., 1298
Gomez-Pastrana, D., 17
Gondry-Jouet, C., e154
González, J. M., e158
Gooch, W. M., III, 1798
Gooze, P. B., e17
Gorbach, S. L., I
Gorka, W., e87
Gottelher, N. P., 559
Gout, O., 510
Grace, C. J., 1651
Graham, D. Y., 1387
Graninger, W., 838
Grant, B., 352
Grecka, P., 1718
Green, W. K., 23
Greenberg, P. D., 1117
Greer, W., 50
Griffin, P. M., 331
Griffith, B. E., 1547
Griffith, D. E., 432, 1547
Grinspoon, S., 130
Gripshover, B. M., 1487
Grossman, R., 436
Grulich, A. E., 989
Grupo de Estudio de Castilla la Mancha de Enfermedades Infecciosas Group, 506
Guarner, J., 1448
Gucalp, R., 381
Gueit, I., 326
Guerrant, R. L., 331
Gülbas, Z., e59
Gumbo, T., 1235
Günther, S., 144
Günzelmann, S., e1
Gurland, I. A., 667
Gutiérrez, F., 149
Habib, G., 1440
Hachem, R., 186
Haddad, M. C., 820
Hadigan, C., 130
Hadler, S. C., 522
Hajjeh, R. A., e151, 708, 1110, 1215, 1448
Hakim, J. G., 1235
Halperin, S. A., 1691
Hamilton, J. D., 605
Hamor, R., 1562
Hamrick, H. J., Jr., 124
Han, X. Y., e145
Hanauer, S. D., 1010
Hanf-Kristufek, L., 990
Hanna, G. J., 774
Hannah, E. L., e151
Hannoun, C., 144
Hanson, D. L., 794
Harle, J.-R., 1440
Harper, M. B., 566
Harrell, C. C., 990
Harris, A. D., 317, 1055
Harris, J. A. S., 1249
Hart, S. M., 1430
Harwell, J. L., e102
Hatcher, J. C., 1117
Hathorn, J. W., 381
Hawkins, E., 801
Hayden, M. K., 826
Hebert, J., 1511
Hedderwick, S. A., 367
Heenen, M., e9
Heiskanen, L., 1141
Heiss, M., 832
Helft, J., 1108
Hemmel, D. L., 103
Henderson, H., 1215
Hendricks, L., 527
Hennequin, C., e154
Hennessy, T., 331
Henriques Normark, B., 552
Herbich, K., 838
Herchline, T. E., e53
Hermann, G., 1104
Hermida-Escobedo, C., 530
Herwaldt, B. L., 1010
Hetherington, S. V., 36
Heurter, H., 1674
Hewitt, R. G., 1517
Heyman, W., 505
Hidalgo, A. M., 149
Hide, M., 302
Hien, T. V., e78
Higgs, E. S., 1517
Himmelman, A., 1233
Hisada, M., 515
Ho, P. L., 701
Ho, W. G., 381
Hoa, N. T. T., e78
Hoban, D. J., S81
Hockmann, J., 1643
Hoff, J., 963
Hoffman, R. E., e151
Hoffman, T., 662
Hoffner, S. E., 373
Hohmann, E. L., 263
Hollender, E. S., 323, 515
Holloway, M., 1215
Holmes, K. K., 1313
Holtz, T. H., e124
Hong, J.-Y., 1423
Hooper, D. C., S9
Horn, R., 381
Horner, P., 995
Hornick, R., 396
Horowitz, H. W., 862
Hospedales, J., 890
Hota, B., 826
Hotez, P. J., e111
Houston, S., 150
Hsieh, S.-M., 1361
Hudson, M. M., 36
Hughes, W. T., 36, 855
Hung, C.-C., 1361
Hunter, P. R., 1795
Huovinen, P., 1608
Hurst, L., 1500
Hurwitz, S., 44
Husson, J., e154
Hutchins, G. M., e36
Iannini, P. B., 1112
Ibrahim, E., 515
Idigoras, P., e158
Indar-Harrinauth, L., 890
Infectious Diseases Society of America, 604
Ing, M. B., e39
Inglesby, T. V., 436
Inoue, T., 1325
International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer, 1532
International-Infectious Disease Society for Obstetrics and Gynecology-USA, 103
Iseman, M. D., 643, 1506
Ismail, A., 1235
Itakura, O., e57
Jacobs, M. R., 1463
Jacobson, K., 539, 871
Jacquot, S., 326
Jamal, F., 1463
Jazbec, J., e31
Jenkins, J., e124
Jenny-Avital, E. R., 322, 1227
Jensen, E., 396
Jiang, Z.-D., 1706
Jie, C., 650
Jimenez-Lucho, V. E., 1117
John, C. C., 9
Johnson, D., 1090
Johnson, D. W., 815
Johnson, G., 1674
Johnson, R., 708
Johnson, R. M., 1628
Johnson, S. C., 815
Johnson, W. D., 255
Joiner, K., 255, 755
Joint Study Group on Hepatitis C Virus of the French National Society of Internal Medicine and the French Society of Infectious Diseases (GERMIVIC Study Group), 1207
Jokinen, C., 1141
Jones, B., 662
Jones, J. L., 794
Jones, R. C., 694
Jones, R. N., S81, S104, S114, S133, S146, S156
Jorgensen, J. H., e140, 295
Juffermans, N. P., 650
Jurado, R., 1103
Jurriaans, S., 1095
Just-Nubling, G., 1235
Juvonen, H., 1141
Kachur, S. P., e124
Kajon, A. E., 694
Källénus, G., 552
Kallinen, S., 1141
Kang, M., 801
Kanno, M., 313
Kantarjian, H., 539
Kao, A., 708
Kaplan, E. L., 1798
Kaplan, J. E., 794
Karanes, C., 546
Karchmer, A. W., 255, 419
Karchmer, T. B., 1055
Kato, K., 989
Kato-Maeda, M., 1580
Katsilambros, N., 1718
Katti, M. K., 1114
Kauffman, C. A., 367, 1215
Kawakami, Y., 1399, 1408
Kawano, K., 989
Kazanjan, P., 766
Kazmierczak, J. J., 1434
Kedlaya, L., e39
Kelen, G. D., 655
Keller, M. J., 140
Keller, N., S133
Keravel, Y., 1371
Kern, W. V., 832
Kessler, H. A., 1635
Ketali, L., 300
Keystone, J. S., 757
Khan, M. Y., 1172
Khan, S. A., 884
Khatib, R., 1381
Kiehl, M. G., e1

- Kiehn, T. E., 1034
 Kikuchi, K., 1399, 1408
 Kikuta, H., e57
 Kim, S., 1463
 Kim, W.-S., 1423
 Kimmel, A. D., 783
 King, S., 1685, 1554
 Kiraz, N., e59
 Kirsch, M., 877
 Kirsten, D., e1
 Kish, M. A., 851
 Kitamura, T., 1325
 Klustersky, J., 1532
 Klausner, J. D., 1313
 Kleemola, M., 1141
 Klein, J., 546
 Klein, J. O., 1155
 Klosters, G., 311
 Kneen, R., 204
 Knockaert, D., 191
 Knox, T. A., 1769
 Kobayashi, K., e57
 Koehler, J. E., e124
 Koh, Y.-Y., 1423
 Kok, R. H. J., 311
 Komatsu, K. K., 1448
 Kong, P.-M., 1506
 Konoplev, S., 539
 Kontoyiannis, D., e94, e145, 871
 Korn, L., 667
 Koskela, M., 1141
 Kovačičová, G., 1110
 Kozarsky, P. E., 757
 Krasemann, C., S22, S51
 Krčmery, V., 1110, 1656
 Kremsner, P. G., 838
 Krubel, S., 116
 Kruuner, A., 373
 Kubin, R., 1112
 Kubitz, D., S47
 Kubota, M., e57
 Kularatne, R., 289
 Kumar, P. N., 116
 Kumasaka, K., 989
 Kumwenda, N., 1496
 Kuppermann, N., 1004
 Kurosu, T., 1325
 Kuster, R. L., 1010
 Kuter, B., 396
 Kwok, T. K., 701
 Lalitha, M. K., 1463
 Lämmle, B., 1338
 Lamoste, T. J., e100
 Lancaster, D., 1215
 Landman, D., 1245
 Lane, H. C., 1738
 Lane, J. E., e107
 Lange, J. M. A., 1095
 Lapin, R. H., 1518
 La Rosa, A. M., 871
 la Rosa, R., 633
 Larruskain, J., e158
 Larsen, B., e69
 Laurel, V. L., 1639
 Lautenbach, E., 1162
 Lauw, F. N., e81
 Law, M. G., 989
 Layton, M., 277
 Lazarus, H. M., 381
 Leal, M., 633
 Lechi, A., e143
 Lederman, H. M., e13
 Lederman, M. M., 1487
 Ledger, W. J., 103
 Lee, H.-J., 1423
 Lee, N. Y., 1463
 Lee, S.-I., 1463
 Le Faou, A., 1290
 Legakis, N., S94
 Le Gall, J.-R., 30
 Leighton, J. A., 1448
 Leinonen, M., 1141
 Lell, B., 838
 Lemée, V., 1792
 Leoni, P., 1414
 Leport, C., 1776
 Lerner, A. M., 1657
 Lesprit, P., 1371
 Levina, K., 373
 Levine, B., 1244
 Levine, O. S., 824
 Lewis, R. E., e94
 Li, H., 23
 Li, J., 1463
 Liance, M., 1371
 Lieberman, J., 1651
 Liedtke, L. A., 270
 Lillehoj, E., 842
 Lin, S.-J., 358
 Lin, T.-Y., 1463
 Liñares, J., S104
 Lindsley, M., e151, 1448
 Linezolid Nosocomial Pneumonia Study Group, 402
 Lipsitch, M., 1044
 Lisbon, A., e120
 Lissen, E., 633
 Lister, P. D., S33
 Littenberg, B., 1651
 Little, R., 1373, 1628
 Liu, G., 824
 Liu, G. T., 173
 Livingood, W. C., 170
 Loan, H. T., 243
 Loc, P. P., e78, 243
 Lockman, S., 373
 Logan, N. D., 1387
 Loisanche, D., 877
 Long, H. Y., 838
 Longhurst, C. A., 1659
 Longuet, P., 1776
 Lopez, A. S., 1010
 López, F., 149
 Lopez, F. A., 1430
 López-Barrio, A. M., 17
 López-Lopategui, M. C., e158
 Lorente, C. A., 1378
 Lorenz, E., 302
 Losina, E., 783
 Louie, T. J., 381
 Low, D. E., S133
 Lubritz, G., 1643
 Lucet, J.-C., 1393
 Luckner, D., 838
 Lugoboni, F., e143
 Luna, M., 539
 Lund, B., 1384
 Lundstrom, T., 1602
 Lupi, C., 1241
 Lyke, K. E., 1178
 Lyon, G. M., 1448
 MacArthur, J. R., e124
 MacGregor, D., 1674
 Macías, J., 633
 MacKnight, C., 1726
 Maes, A., 191
 Maestre, A., 149
 Magnusson, M., 1523
 Mah, M. W., 1172
 Maiwald, M., 457
 Maiz, L., 1298
 Mäkelä, P. H., 1141
 Malaty, H. M., 1387
 Malley, R., 1004
 Mamikoglu, L., 1658
 Manalastas, R., 1313
 Mandell, G. L., 255
 Mandell, L. A., S72
 Manegold, C., 144
 Manning, W. J., e120
 Marchi, A., 1241
 Mariuz, P. R., 483
 Markovitz, D. M., 983
 Márquez, M., 159
 Marr, K., 321
 Marrón, A., 1024
 Martens, M., 103
 Martín, C., 159
 Martínez, F., 1024
 Martínez-Alfaro, E., 506
 Martínez-Sandoval, F., 1706
 Martino, P., 1532
 Martín-Sánchez, J., 633
 Marty, F., 1108
 Maruchi, N., 1399, 1408
 Mashinter, L., 150
 Massung, R. F., 979
 Masuell, C. P., 1104
 Mathewson, J. J., 1706
 Matsumoto, A. K., 502
 Matteelli, A., 1063
 Matts, J. P., 623
 Matushek, M., 826
 May, T., 1494
 Mayer, K. H., 476
 Mayxay, M., 653
 Mazzoli, F., 1241
 McComsey, G., 1487
 McCullers, J. A., 1456
 McElmeel, M. L., e140
 McEniry, D., 396
 McFarland, E. J., 801
 McGeer, A., 1554
 McGovern, B., 492
 McGowan, K., 492
 McKechie, D. B., 979
 McLeod, G. X., 352
 McMinn, P., 236
 McNamara, J., 801
 McNeil, M. M., e78
 McNeil, S. A., 367
 Mecenero, V., e143
 Mediwal, R., 534
 Mehta, S. D., 655
 Meigs, J. B., 130
 Meissner, H. C., 1004
 Mekonto-Dessap, A., 877
 Mele, A., 1414
 Memish, Z. A., 1172
 Mendelson, M. H., 1104
 Mermel, L. A., 1249
 Mertens, R., 302
 Merz, W. G., 1178
 Meschievitz, C., 170
 Metz, D., 1643
 Meyer, J., S51
 Meynard, J. L., 297
 Meyohas, M. C., 297
 Mezzelani, P., e143
 Michael, J. R., 498
 Mielke, J., 1235
 Mies, C., 662
 Mikol, J., 510
 Miller, D. L., 975
 Miller, J., 662
 Miller, J. M., 605
 Miller, L. G., 1110
 Miller, N. S., 1178
 Miller, W. C., 124
 Minari, A., 186
 Miotti, P. G., 1496
 Mirete, C., 149
 Mirza, N., 871
 Mitchell, P. D., 1434
 Moench, T., 476
 Mofenson, L., 801
 Molina, J. M., 1776
 Monif, G. R. G., e69, 103
 Monira, S., 884
 Monmeneu, J. V., 149
 Montanari, M., 1414
 Moore, C. C., e107
 Moore, D. A. J., 469
 Moore, G., 44
 Moore, T., e122
 Mootrey, G. T., 1273
 Mora, A., 149
 Moran, G. J., 573
 Mori, S.-i., 1325
 Morillas, F., 633
 Morris, A., 1691
 Morris, A. J., 647
 Mortelmans, L., 191
 Moschella, S. L., 930
 Mousharafieh, U., 820
 Mower, W. R., 573
 Mowgli Study Group, 1281
 Moylett, E. H., 1018
 Mtimavalye, L., 1496
 Mueller-Rizner, N., 1434
 Mundy, L. M., 124
 Murdoch, D., 647, 975
 Murphy, E. L., 116
 Murray, C. K., e140

- Murray, K. A., 498
Musher, D. M., 307, 534, 1511
Nace, E. M., 1010
Nachamkin, I., 331
Naeyaert, J.-M., e9
Nagarajan, L., 236
Nahar, S., 884
Nahum, R., 1371
Nájera, R., 1732
Nakama, H., 1399, 1408
Nakamura, T., 1399, 1408
Nakamura-Uchiyama, F., e171
Nakase, J. Y., 573
Narita, M., 323, 515
Nasti, G., 1100
Natarajan, S., 1104
Nathwani, D., 728
National Institute of Allergy and Infectious Diseases Mycoses Study Group, 1215
Navarro, J., 17
Nawa, Y., e171
Neill, M., 331
Nelson, C., 1039
Nelson, K. E., 955
Nelson, S., 1674
Nerad, J. L., 1635
Nessa, K., 884
Neuville, S., 30
Neuzil, K. M., 847
Newdow, M., 573
Newell, J. P., e124
Newton, P., 653
Ng, T. K., 701
Nga, N. T. T., 204
Nguyen, Q., 539
Nhan, N. T., 204
Norgren, M., e24
Normark, S., 552
Notario, G. F., 1798
Novak, R., 552
Nowak-Węgrzyn, A., e13
Noyola, D. E., 1018
Oberhelman, R. A., 1567
Offidani, M., 1414
Ofotokun, I., 983
O'Grady, N., 1249
Ohashi, K., 1325
Okamura, A., e57
Olavarria, E., 413
Oldfield, E. C., III, 1231
Oliphant, T. H., 402
Oliver, A., 1298
Olivieri, A., 1414
Olsen, K. M., e83
Oltman, S., 1010
Onah, D. N., e171
O'Neill, W., 1657
Ong, S., 573
Onozawa, Y., 1325
Ooi, W. W., 930
Orlandi, P. A., Jr., 1010
Orlovic, D., 44, 289
Ormerod, L. D., 1661
Örtqvist, A., 552
Osborne, N. G., 103
Osterholm, M. T., 331
O'Toole, T., 436
Otto, G., 1523
Ou, J. T., 520
Owens, S., 1615
Ozden, S., 510
Pachón, J., 587
Paesmans, M., 1532
Pahissa, A., 1024
Paladino, J. A., S39
Palatnick, W., 636
Palau, L., e166
Paltiel, A. D., 783
Pani, A., e143
Pankey, G. A., e166
Pantalena, M., e143
Pappas, P. G., 518, 1215, 1319
Parent, E. M., 1470
Parise, M. E., e124
Park, K.-H., 1423
Park, S., 1034
Parola, P., 897
Parry, M. F., 352, 1245
Parsonnet, J., 1470
Pasha, T. M., 1448
Patel, J. B., 1162
Patel, R., 1540
Pato-Mesola, V., 1313
Paton, N. I., e129
Patrick, C. C., 36, 1456
Patterson, T. F., 295
Pavlov, R., e176
Paya, C. V., 596, 1237
Pearson, T. A., 1456
Peck, K. R., 1463
Pediatric AIDS Clinical Trials Group 230 Collaborators, 801
Peetermans, W. E., e9, 527
Peipert, J., 476
Peitsch, W. K., e145
Peltola, H., 64, 715
Pelton, S. I., 1155
Pendle, S., 44
Perencevich, E. N., 317
Perera, J., 1463
Perez, C., e105
Pérez-Trallero, E., e158
Perkins, B. A., 708
Perlin, D., 1034
Perlman, D. C., 623
Perronne, C., 1207
Peters, G., 1643
Peters, W., 546
Peterson, L. R., 605
Petric, M., 1674
Petrucca, A., e15
Pettus, P. T., 140
Pfalter, M. A., S114, S156
Phair, J., 396
Phan, H. M., 307, 534
Phantumchinda, K., e117
Phelan, M., 1215, 1448
Phetsouvanh, R., 653
Phillips, P., 845
Phipatanakul, W., e13
Phongmany, S., 653
Phuong, C. X. T., 204
Phuong, N. T. Q., 204
Pickering, L. K., 331
Piecuch, S., 130
Piedra, P. A., 1423
Pierce, K., 1651
Pierre, C., 991
Pietrobon, P., 170
Pigrau, C., 1024
Pineda, J. A., 633
Pinedo, A., 159
Piñero, L., e158
Pinner, R. W., 573
Pitchenik, A. E., 323
Pitlik, S., e176
Pizov, G., 1502
Platt, R., 140, 686
Pleconaril Treatment Registry Group, 228
Plikaytis, B. D., 708
Plotkin, S. A., 1068
Polish, L. B., 1331
Polywka, S., 144
Ponce, C. A., 855
Pons, J.-L., 326
Popara, M., 44
Portegies, P., 1095
Portsmouth, S., 469
Poulakou, G., 1718
Powderly, W. G., 124
Pozio, E., 638
Prabhakar, P., 890
Pratlong, F., 302
Press, N., 808
Price, P., 325
Prijanto, M., 1039
Prince, T. L., e17
Principi, N., 1281
Prins, J. M., 1095
Procop, G. W., 1589
Puerzer, M., 979
Puklin, J. E., 1661
Pur, S. L., 694
Pyörälä, K., 1141
Quagliarello, V., 755
Quaglio, G., e143
Quang, V. M., e78
Quinn, T. C., 655
Raad, I., e94, 186, 539, 871, 1249
Rabaud, C., 1494
Raccurt, C. P., e154
Raffalli, J. T., 862
Raffi, F., 162, 963
Raguin, G., 1207
Rahman, M., 884
Ramanathan, J., 1381
Ramaswamy, R., 1231
Ramchatesingh, J. E., 1387
Ramgopal, M., 662
Ramon, J., 822
Ramphal, R., S146, 381
Ramsay, A., 653
Ranger-Rogez, S., 197
Raoult, D., 897, 1440
Rastegar, D. A., 502
Raveh, D., 559
Ravnik, I., e31
Razzouk, B. I., 1456
Reagan-Cirincione, P., 220
Rebuck, J. A., e83
Reddy, B. T., e145
Reed, G. W., 847
Reed, K. D., 1434
Reeves-Hoché, M. K., 170
Regnery, H., 1784
Régnier, B., 1133
Reid, K. C., 1540
Reilly, D. T., 419
Reimer, L. G., 498
Reingold, A., 708
Reiter, C., 1112
Reller, L. B., 331, 975
Relman, D. A., 457
Rennie, R., S146
Residori, M., e143
Rex, J. H., 518, 1191, 1713
Richard, P., 162
Richardson, S., 1554, 1674
Richet, H., 162
Riddell, D., 862
Riederer, K. M., 1381
Rietschel, P., 130
Rigter, A., e97
Rijkers, G. T., 1700
Ritchie, D. J., 1373
Riveau, G., e154
Rivero, A., 159
Roberson, P. K., 36
Roberts, N., 150
Roberts, S. A., 647
Rodriguez, N., e158
Roemer, E., e1
Rogers, D., 708
Rollinghoff, M., 302
Rolston, K., e145, 539, 871
Romero, G. A. S., 1304
Rönnberg, P.-R., 1141
Rosa, A., e154
Rosado-Santos, H., 498
Rose, G., 636
Rosenberg, Z., 476
Rosenstein, C., 352
Rosenstein, N. E., 708
Rosenthal, E., 1207
Ross, L. L., 636
Ross, M. J., e120
Rotbart, H. A., 228
Roth, D., 662
Rothman, R. E., 655
Rouslanova, I., 842
Roussel-Delvallez, M., S81
Ruben, F. L., 170
Rubinger, D., 1502
Rubinstein, E., 402, 728, 822
Rudensky, B., 559
Ruef, C., 581
Rupoli, S., 1414
Rupp, M. E., e83
Rutala, W. A., 446, 1348
Saba, R., 1658
Sacchi, L., 638
Sacchini, D., 638

- Sack, D., 396
 Sack, R. B., 331
 Sacks, L. V., 44
 Sader, H. S., S104, S156
 Saengwonloy, O., 955
 Sagar, B., 153
 Sagui, E., 991
 Sahgal, N. B., 826
 Saikku, P., 1141
 Sajjad, Z., 1366
 Sakamaki, H., 1325
 Sakashita, C., 1325
 Sakoulas, G., e120
 Salata, R. A., 1487
 Sale, G., 214
 Salminen, S., 1577
 Salzman, D., 1319
 Samore, M. H., 317, 1055
 Sampathkumar, P., 1237
 Samper, S., 159
 Samra, Z., e176
 Samson, I., 527
 Sanchez, H., e1
 Sánchez, M. A., 159
 Sánchez-Quijano, A., 633
 Sanders, C. C., S1
 Sanders, C. V., 1430
 Sanders, L. A. M., 1700
 Sandlund, J. T., 36
 Sandridge, A., 50
 Santana, V. M., 36
 Santolaya, M. E., 855
 Santos, J., 159
 Sanz, M., 1532
 Saravolatz, L. D., 1562
 Sarid, R., 1502
 Saulsbury, F. T., e137, 464
 Sax, P., 130, 140
 Scalari, P., 1414
 Scanvic, A., 1393
 Schaffner, A., 1233
 Schaffner, W., 23
 Schantz, P. M., e111
 Scheib, R., 492
 Schellenberg, R. R., 1685
 Schentag, J. J., S39
 Schioppa, O., 1100
 Schlech, W. F., III, 1519
 Schlemmer, B., 30
 Schlesinger, Y., 559
 Schmader, K., 1481
 Schmid, D., 838
 Schmidt, E. V., 1004
 Schmitz, F. J., S114
 Schöniar, G., 302
 Schranz, J., 358
 Schroeder, J., 842
 Schuhmacher, H., 1494
 Schulman, G., 23
 Schuster, M. G., 391
 Schwartz, F., 1502
 Schwarz, T., 1643
 Schwebke, J. R., 325
 Seage, G. R., III, 783
 Sebt, A., 1034
 Seger, D. L., 686
 Segreti, J., 694
 Segura, J. C., 506
 Seiler, S. M., 1331
 Semba, R. D., 1496
 Senining, R. C., e100
 Sentinel Health Unit Surveillance
 System Pertussis Working
 Group, 1691
 SENTRY Participants Group,
 S114
 Senzilet, L. D., 1691
 Sepkowitz, K. A., 1034
 Sereti, I., 1738
 Shabtai, M., 822
 Shah, M. A., 647
 Shahzad, R., e100
 Shamoon, A., e87
 Sharara, A. I., 820
 Sharghi, N., e111
 Sharma, M. D., 153
 Sheagren, J. N., e131
 Shenep, J. L., 36, 1456
 Sherertz, R. J., 1249
 Shevitz, A. H., 1769
 Shibl, A. M., 1463
 Siegel, M., 972
 Simdon, J., 1623
 Simonart, J.-M., e9
 Simonart, T., e9
 Simpson, J. A., 204
 Singh, N., 742
 Singleton, T. P., 983
 Sirisanthana, T., 955
 Siwji, S., 1235
 Sixbey, J. W., 36
 Skahan, K. J., 1215
 Slain, D., 321
 Slater, K., 979
 Slaven, E. M., 1430
 Slobod, K. S., 36
 Slutsker, L., 331, 573
 Smaczny, C., 1648
 Small, P. M., 1580
 Smayevsky, J., S114
 Smego, R. A., 289
 Smilack, J. D., 1448
 Smith, B., 1691
 Snoeck, R., e62
 Snyderman, D. R., 492
 Sobel, J., 518, 1191, 1602, 1661
 Sočan, M., e31
 Soeiro, R., 1108
 Soewignjo, S., 1039
 Solera, J., 506
 Solomon, T., 204
 Song, J.-H., 1463
 Soto, N. E., e100
 Sovric, M., 838
 Spaendonck, M. A. E. C., 2
 Spanjaard, L., 1700
 Speelman, P., 650
 Spellberg, B., 76
 Spika, J. S., 1691
 Stadtmauer, E., 391
 Stahl-Avicoli, A., e100
 Stambaugh, J. J., 323, 515
 Stamm, W. E., 255
 Stanley, S., 1373
 Stanley, T., 130
 Starlin, R., 1373
 Stass, H., S47
 Steffen, R., 1706
 Steinbach, G., 832
 Steiner, T. S., 331
 Steinhoff, M., 1039
 Stellini, M. A., e90
 Stén, M., 1141
 Stephens, J. L., e107
 Stevens, D. L., e24
 Stoeckli, T. C., 836
 Stone, D., 492
 Storch, G. A., 1628
 Stout, J. E., 1562
 Stratov, I., 236
 Strausbaugh, L. J., 270
 Stroobants, S., 191
 Stroud, T. P., 1319
 Stutman, P., 307
 Su, L., 686
 Suankratay, C., e117
 Suh, K. N., 483
 Sultan, Z., 884
 Sundar, K. M., 498
 Sutanto, A., 1039
 Svanborg, C., 1523
 Svensson, M., 1523
 Svetlansky, I., 1110, 1656
 Szilak, I., 1108
 Tachawiboonsak, W., e117
 Tack, K. J., 381
 Taddonio, R., 352
 Taha, T. E., 1496
 Talan, D. A., S64, 573
 Talbot, R., 708
 Tam, D. T. H., 243
 Tam, W.-H., 1376
 Tamburrini, A., 638
 Tan, J. S., 1562
 Tang, Y.-W., 23
 Tanikawa, S., 1325
 Tankovic, J., e92
 Tappero, J. W., 373
 Tarkiainen, A., 1141
 Tarr, P., 331
 Tarrand, J., 539
 Tashima, K. T., 970
 Tateishi, H., e22
 Tauxe, R. V., 331
 Taylor, G., 167
 Taylor, S. L., 647
 Taylor-Robinson, D., 995
 Teague, B. A., e111
 Tee, N. W.-S., e129
 Tenorio, A. R., 826
 Tenover, F. C., 605
 Teo, T.-P., e129
 Territo, M. C., 381
 Teutsch, S. M., 358
 Theodore, S., 1155
 Thielman, N. M., 331
 Thien, V. V. S., 1685
 Thiéry, G., e92
 Thimmappa, B., 515
 Thomas, B., 995
 Thomas, E., 300
 Thomas, K., 1463
 Thomason, J. L., 103
 Thompson, S., 1706
 Thompson, S. J., 1456
 Thomson, M. M., 1732
 Thomson, R. B., Jr., 605
 Thomson-Carter, F., e97
 Thonell, L., 44
 Thorpe, C. M., 1517
 Thursky, K., e65
 Thuy, T. T. N., 243
 Ticona, E., 808
 Tiengrim, S., 1463
 Tilden, R. L., 862
 Tillotson, G., S22, S51, S72, 1112
 Tillotson, G. S., 1189
 Timpone, J., 972
 Tirelli, U., 1100
 Tompkins, L. S., 605
 Tønning, B., 987
 Torresi, J., e65
 Torrey, E. F., 842
 Torronteras, R., 17
 Totsuka, K., 1399, 1408
 Towne, L., 1178
 Traccard, I., 197
 Trenholme, G. M., 826
 Trupl, J., 1656
 Truskinovsky, A. M., e36
 Tsang, K. W. T., 701
 Tse, W. S., 701
 Tselis, A. C., e90
 Tsukahara, M., e22
 Tsuneoka, H., e22
 Tuazon, C. U., 1313
 Tukiaainen, H., 1141
 Tuomanen, E., 552
 Turk, B. K., 140
 Turnidge, J., S146, S156
 Uchida, M., e22
 Uehara, Y., 1399, 1408
 Ulloa, A. V., 855
 Uzun, Ö., e59, 1713
 Vachon, F., 1133
 Valassina, M., 1241
 Valdez, H., 1487
 Van, P. H., 1463
 van den Hof, S., 2
 Vander Heide, R. S., 313
 van der Horst, C., 124
 van der Kraak, P. H., 2
 Vandermause, M., 1434
 van der Meer, J. T. M., e81
 van der Poll, T., e81, 650
 van Deventer, S. J. H., 650
 van Dissel, J. T., 323
 Van Gilder, T., 331
 Van My, N., 204
 Vanoli, C., 581
 Van Thien, C., 204
 Van Valckenborgh, I., e62
 Van Vooren, J.-P., e9
 Van Wijngaerden, E., 527

- Vargas, S. L., 855
 Vaudry, W. L., 1637
 Veenstra, J., 650
 Venard, V., 1290
 Venot, C., 197
 Vento, S., e143
 Ventura, W., 50
 Verbon, A., 650
 Verenkar, M. P., 1706
 Verhoef, J., S104, S156
 Verleysen, A., e9
 Verraes, S., e9
 Vexiau, P., 30
 Veyssier, P., 1207
 Vignon, P., 197
 Villasenor-Sierra, A., e24
 Vinitius de Farias Guerra, M., 1304
 Viral Activation Transfusion Study, 116
 Visca, P., e15
 Viscoli, C., 1532
 Vivar, R., S30
 Vivarelli, A., 1241
 Vizzi, E., 1126
 von Eiff, C., 1643
 Vu, C. K.-F., e129
 Vugia, D., 708
 Vuori-Holopainen, E., 715
 Wagenaar, J. A., e97
 Walker, B. D., 1756
 Wallace, R. J., Jr., 1547, 1648
 Wallach, F., 116, 667
 Walls, J. J., 862
 Walmsley, S., 1554
 Walsh, T. J., 518
 Walter, E. A., e140, 1639
 Wang, S., 153
 Wang, V. J., 1004
 Wang, Y. C., 373
 Wanke, C. A., 1710
 Wara, D. W., 801
 Ward, J. W., 794
 Ward, K. N., 413
 Ware, A. J., e122
 Warnock, D. W., 1448
 Warren, D. K., 1331
 Warsa, U. C., 1463
 Watson, A., 660
 Watters, D., 1623
 Weber, D. J., 446, 1348
 Webster, A. D., 228
 Wegener, S., S22
 Weinberg, A., 815
 Weingarten, M. S., 949
 Weinstein, M. C., 783
 Weinstein, R. A., 826
 Weiss, H., 325
 Weissman, S. B., 1487
 Wellens, W., e62
 Weller, P. F., 317
 Wenzel, R. P., 1538
 Werner, S. B., 708
 West, D. C., 1659
 Wheat, L. J., 1215
 Whimbey, E., e145, 539, 871
 White, A. C., Jr., 153, 1516
 White, N. J., 204, 243, 653
 Whittington, W. L. H., 1313
 Wi, T., 1313
 Widjaya, A., 1039
 Wilde, H., e117
 Wilfert, C. M., 605
 Williams, P., 1615
 Wills, B., 204
 Wilson, M., 660
 Wilson, M. E., 1378, 1589
 Wilson, P. W. E., 130
 Winkelstein, J. A., e13
 Winokur, P. L., S94
 Winston, D. J., 381
 Witz, F., 1290
 Wocker, E. L., e1
 Wolf, D. G., 1502
 Wolff, M., 1133
 Wolfhagen, M. J. H. M., 311
 Wolfs, T. F. W., e97
 Won, K. Y., 1010
 Wong, M., 1034
 Wong, S. J., 1784
 Wong, S. S., e39
 Wood, D., 307
 Woodhouse, L., 170
 Woodhouse, S., 1795
 Woolley, I. J., 1487
 Wormser, G. P., 862
 Wu, J.-L., 1463
 Wunderink, R. G., 402
 Wuthiekanun, V., 653
 Wywiol, A., 144
 Yang, Y., 824, 1463
 Yasmin, L., 884
 Ye, Y., 1554
 Yee, T. T., 1463
 Yeo, W., 1376
 Yiannoutsos, C. T., 1517
 Yinnon, A. M., 559
 Yip, M. C., 1639
 Yolken, R. H., 842
 Yoshioka, M., e57
 Yu, D. T., 686
 Yuen, K.-y., 846
 Yukna, M., 352
 Zakotnik, B., e31
 Zbinden, R., 581
 Zeller, B., 1784
 Zenilman, J. M., 655
 Zervos, M., 1657
 Zhang, H., 783
 Zheng, H., 1325
 Zhong, S., 1376
 Zinkernagel, A. S., 1233
 Zwaan, F., e87

SUBJECT INDEX

- Abiotrophia* infections, bacteremia, drug-resistant, e140
 Abortion, spontaneous, in brucellosis, 1172
 Abscess
 abdominal, due to *Brucella*, 1024
 brain
 due to *Aspergillus*
 in bone marrow transplantation, 1319
 treatment, e137
 due to *Streptococcus intermedius*, treatment, e131
 breast, due to *Staphylococcus aureus*, toxic shock syndrome in, 1470
 due to *Edwardsiella tarda*, 1430
 due to *Fusarium*, in heart-liver transplantation, 1237
 liver, due to *Fusobacterium nucleatum* [letter], 326
 due to *Salmonella*, 263
 spinal epidural, in pediatric patients, 9
 due to *Streptococcus intermedius*, hepatopulmonary syndrome in,
 treatment, e131
 due to *Streptococcus milleri* group, 1511
 tubo-ovarian, Centers for Disease Control and Prevention guidelines,
 103
 visceral
 due to *Brucella suis*, e129
 in HIV infection, *Mycobacterium avium* complex prophylaxis and,
 1615
Acinetobacter infections
 catheter-related, guidelines, 1249
 resistance in, global, S104, S156
 Acquired immunodeficiency syndrome (see Human immunodeficiency virus infection)
 Acrodermatitis continua of Hallopeau, digital, 431, 505
Actinomyces infections, pathology, 1589
 Acyclovir
 for cytomegalovirus infections, prophylactic, 596
 for eczema herpeticum, 1480, 1500
 for herpes simplex virus, in HIV infection, 611
 for herpes zoster, 1481
 for HIV opportunistic infections, lymphoma and [letter], 989
 resistance to, herpes simplex virus, 611
 Adenovirus infections
 in bone marrow transplantation, 871
 hemorrhagic cystitis in, 1325
 pathology, 1589
 respiratory, in Korean children, 1423
 in stem cell transplantation, 1290
 type 7d2, outbreaks, 694
Aeromonas infections, diarrhea, practice guidelines, 331
 Aerosol treatment, with aminoglycosides, for tuberculosis, 44
 AIDS (see Human immunodeficiency virus infection)
 Albendazole
 for gnathostomiasis, e154
 for hydatidosis, thigh muscle, e65
 resistance to, *Giardia lamblia*, 1792
 Alcohol, in hand cleansing gel, artificial fingernail colonization and, 367
 Allergic reactions
 to meningococcal vaccines, 1273
 to penicillins, skin testing for, 317, 1685
 Alternariosis, in diabetes mellitus, 1178
 Amantadine, for hepatitis C, 830
Amblyomma species, review, 897
 Amebiasis, practice guidelines, 331
 American Hospital Association, on Medicare overcharges for pneumonia, Current News, May 15
 Amikacin
 for meningitis, tuberculous, 643
 resistance to, 1162
 Acinetobacter, S104
 extended-spectrum β -lactamase-producing organisms, S94
 Pseudomonas aeruginosa, S146
 Stenotrophomonas maltophilia, S104
 Aminoglycosides
 for *Staphylococcus aureus* infections, vancomycin-resistant, 108
 for tuberculosis, refractory, 44
 Amitriptyline, for herpes zoster, 1481
 Amoxicillin
 resistance to, *Haemophilus influenzae*, S81
 for syphilis, in HIV infection, 611
 Amphotericin B
 for alternariosis, in diabetes mellitus, 1178
 for aspergillosis, 358
 in bone marrow transplantation, e94
 for *Candida lusitanae* infections, 186
 for candidiasis, in neonates, 1018
 for endocarditis, 50
 for fever, in neutropenia [letter and reply], 320, 518
 for *Fusarium* infections, in heart-liver transplantation, 1237
 for intravascular catheter-related infections, 1249
 kidney failure due to, economic impact of, 686
 lipid formulations, liver injury due to, e87
 nephrotoxicity, 686, 990 [letter]
 for osteomyelitis, due to *Candida*, 527
 for urinary tract infections, due to *Candida*, 1602
 Ampicillin
 for intravascular catheter-related infections, 1249
 resistance to, *Enterococcus*, S133
 Amplicor test, for *Mycobacterium tuberculosis*, in pediatric patients, 17
 Anaerobic organisms, in vaginal flora, e69
 Anatomic pathologist, in infection diagnosis, 1589
 Andes hantavirus infections, nosocomial, prevention, 446
 Anemia
 in babesiosis, 1117
 in malaria, 1133
 in parvovirus B19 infections, 167
 in HIV infection, e122, 1361
 Angiography, coronary, *Corynebacterium jeikeium* endocarditis after, e120
 Animal(s), prion diseases in, 1726
 Animal studies
 moxifloxacin activity, S16, S22
 T lymphocyte type 1/type 2 immunity, 76
 Ankylosing spondylitis, pulmonary fibrosis in, 1062, 1103
 Anorectal infections, in HIV infection, 611
 Anthrax, nosocomial, prevention, 446
 Anthropometry, in HIV infection, 130
 Antibiotics (see also specific antibiotics)
 book reviews, 1245
 lock therapy with, 1249
 prophylactic (see Prophylaxis)
 resistance to (see Drug resistance)
 selection, new β -lactamases and, 1085
 susceptibility to (see Susceptibility testing)
 toxicity, S72
 use patterns, resistance development and, 1044, 1189
 Antibody(ies)
 Haemophilus influenzae, after vaccination, 2
 HIV, 1756
 pneumolysin, in *Streptococcus pneumoniae* infection diagnosis, 534
 streptococci, group A, e24
 T lymphocyte type 1/type 2 immunity and, 76
 Toxoplasma gondii, in schizophrenia, 842
 Antidepressants, for herpes zoster, 1481
 Antigen(s), dose of, in T lymphocyte type 1/type 2 immunity, 76

- Antigen-presenting cells, T lymphocyte type 1/type 2 immunity and, 76
- Antipyretic drugs, for malaria, in pediatric patients, 838
- Aorta, fungal vegetations in, 50
- Area under the inhibitor concentration curve, practical use, S39
- Argasidae (soft ticks), review, 897
- Argentine hemorrhagic fever, nosocomial, prevention, 446
- Arthralgia
- in babesiosis, 1117
 - due to quinupristin-dalfopristin, e83
 - in Whipple's disease, 457
- Arthritis
- rheumatoid, *Bartonella* infections in, e22
 - septic
 - due to *Burkholderia pseudomallei*, 653
 - due to *Staphylococcus aureus*, methicillin-resistant, in injection drug users, 581
- Arthropathy
- fluoroquinolone-induced, S72
 - in parvovirus B19 infections, 167
- Arthroplasty, hip, infections, treatment, 419
- Arthropod infections, pathology, 1589
- Aseptic meningitis
- in enterovirus 71 infections, 236
 - after neurological surgery, vs. bacterial meningitis, 179
- Asian Network for Surveillance of Resistant Pathogens, pneumococci, 1463
- Aspergillus flavus* infections, spinal epidural abscess, in pediatric patients, 9
- Aspergillus* infections
- in bone marrow transplantation, treatment, e94
 - brain, treatment, e137
 - endocarditis, literature review, 50
 - invasive
 - in bone marrow transplantation, 1319
 - mortality in, 358 - pathology, 1589
- Aspiration, lung fluid, for pneumonia diagnosis, in pediatric patients, 715
- Asthma, risk factors, *Toxocara*, e111
- Ataxia, cerebellar, in enterovirus 71 infections, 236
- Atovaquone, for babesiosis, 1117
- AUIC (see Area under the inhibitory concentration curve)
- Avascular necrosis, bone, in HIV infection, 1221
- Azithromycin
- for babesiosis, 1117
 - for brucellosis, 506
 - for diarrhea, 331
 - for legionellosis, failure, 1562
 - for *Mycobacterium avium* complex infections, 1547
 - prophylactic, in HIV infection, 1615
 - resistance to, *Streptococcus pneumoniae*, S81
 - for streptococcal pharyngitis, 1798
- Aztreonam
- for intravascular catheter-related infections, 1249
 - for pneumonia, nosocomial, 402
 - resistance to
 - Escherichia coli*, S94
 - Klebsiella pneumoniae*, S94
 - Proteus mirabilis*, S94
 - Pseudomonas aeruginosa*, S146
- Babesiosis
- in nonspecific fever study, 1434
 - review, 897
 - severe, complications, 1117
- Bacillus cereus* infections
- bacteremia, venous port-related, 1776
 - in immunodeficiency, in pediatric patients, 1456
- Bacteremia
- due to *Abiotrophia*, drug-resistant, e140
 - due to *Bacillus cereus*, in immunodeficiency, in pediatric patients, 1456
 - blood culture for, usefulness, 1651
 - after bone marrow or stem cell transplantation, 391, 546
 - breakthrough, in neutropenia, antifungal prophylaxis and, 1532, 1538
 - due to *Burkholderia pseudomallei*, 653
 - catheter-related
 - in cancer, 1776
 - guidelines, 1249
 - in HIV infection, 1776 - due to *Clostridium tertium*, 975
 - due to *Edwardsiella tarda*, 1430
 - due to *Enterococcus*
 - mortality in, 587
 - resistance in, S133
 - vancomycin resistance and, 1110, 1112 [letter and reply], 1381 - due to *Enterococcus casseliflavus/flavescens*, 1540
 - due to *Enterococcus gallinarum*, 1540
 - due to *Escherichia coli*, virulence factors in, 1523
 - due to gram-negative bacteria, in cancer, prediction, 832
 - due to *Haemophilus influenzae*, resistance in, S81
 - in HIV infection, *Mycobacterium avium* complex prophylaxis and, 1615
 - due to *Moraxella catarrhalis*, resistance in, S81
 - due to *Neisseria meningitidis*
 - epidemiology, 1004
 - protein C replacement in, 1338 - occult, epidemiology, 559
 - due to *Salmonella*, 263
 - due to *Staphylococcus*, e53
 - resistance in, S114 - due to *Staphylococcus aureus*, e53
 - prosthetic joint infections in, 647
 - due to *Stenotrophomonas maltophilia*, susceptibility testing [letter], 1656
 - due to *Streptococcus pneumoniae*
 - pneumolysin antibody detection in, 534
 - resistance in, S81
 - serogroups, in pediatric patients, 1155 - due to *Vibrio cholerae* non-serogroup O:1, e117
- Bacteroides* infections, resistance in, trimethoprim-sulfamethoxazole, 1608
- Bartonella* infections
- in juvenile rheumatoid arthritis, e22
 - pathology, 1589
- Basidiobolomycosis, gastrointestinal, epidemiology, Arizona, 1448
- Basil, *Cyclospora* in, 1010
- BAY γ 3118 (quinolone), activity, S16
- Bee stings, fatal infections after, e36
- Benzathine penicillin G, for syphilis, in HIV infection, 611
- Bichloroacetic acid, for human papillomavirus infections, 611
- Bifidobacterium*, as probiotic, 1567, 1577
- Bile ducts, *Fasciola hepatica* infection, 727, 820
- Binax NOW assay, for *Streptococcus pneumoniae* infections, in pediatric patients, 824
- Biopsy, in infection diagnosis, 1589
- Bioterrorism
- clinical microbiology laboratory services and, 604, 605
 - preparation for
 - TOPOFF exercise, 436
 - West Nile viral encephalitis outbreak observations, 277 - threat of, 675
 - zoonotic diseases in, 446
- Bites

- spider, vs. infections, 595, 636
 tick (see also Ticks, diseases transmitted by; specific diseases)
 review, 897
- Bithionol, for *Fasciola hepatica* infections, 727, 820
- BK virus infections, in bone marrow transplantation, 1325
- Blackwater fever, in malaria, 1133
- Bladder, hemorrhagic cystitis, in bone marrow transplantation, due to adenovirus, 1325
- Blastomycosis
 pathology, 1589
 public health response to, in Colorado, e151
- Bleeding, gastrointestinal, in HIV infection, 1487
- Blood counts, during human granulocytic ehrlichiosis, 862
- Blood culture
 for bacteremia
 occult, 559
 usefulness, 1651
 for pneumonia, vs. lung tap, 715
- Blood transplantation (see Stem cell transplantation)
- B lymphocytes, T lymphocyte type 1/type 2 immunity and, 76
- Bolivian hemorrhagic fever, nosocomial, prevention, 446
- Bone lesions (see also Osteomyelitis)
 avascular necrosis, in HIV infection, 1221
 spinal, in pediatric patients, 9
 due to *Treponema pallidum*, in HIV infection, 667
- Bone marrow transplantation
 adenovirus infections in, 871, 1325
 aspergillosis in, e94
 Candida lusitanae infections in, 186
 hemorrhagic cystitis in, 1325
 infectious complications, after 1 year, 391
 invasive fungal infections in, 1319
 Scedosporium prolificans infections in, e158
- Book reviews
 The Antimicrobial Drugs, 521
 Diagnostic and Therapeutic Antibodies, 670
 Drug Interactions in Infectious Diseases, 1245
 Handbook of Antibiotics, 1245
 Management of Antimicrobials in Infectious Diseases: The Impact of Antibiotic Resistance, 671
 New Concepts in the Immunopathogenesis of CNS Infections, 1244
 Progress in Vaccinology, 522
- Bordetella pertussis* infections
 in adults and adolescents, 1691, 1698
 epidemiology, in elderly persons [letter], 847
- Borreliosis (see Lyme disease)
- Boutonneuse fever, review, 897
- Bovine spongiform encephalopathy, clinical implications, 1726
- Brain
 abscess
 due to *Aspergillus*
 in bone marrow transplantation, 1319
 treatment, e137
 due to *Streptococcus intermedius*, treatment, e131
 infarction, in *Mycoplasma pneumoniae* infections, e31
 infections (see also Encephalitis; Meningitis)
 book reviews, 1244
 surgery on, chemical meningitis after, vs. bacterial meningitis, 179
 tumorlike mass in, due to *Schistosoma mansoni*, 1347, 1371
- Breast abscess, due to *Staphylococcus aureus*, toxic shock syndrome in, 1470
- Breast cancer, bone marrow or stem cell transplantation in, infectious complications, 391, 546
- Breast-feeding, *Helicobacter pylori* infection epidemiology and, 1387
- Bronchiolitis, due to adenovirus, in Korean children, 1423
- Bronchitis
 in HIV infection, *Mycobacterium avium* complex prophylaxis and, 1615
 treatment, moxifloxacin, S51, S64
- Bronchoalveolar lavage fluid, in tuberculosis diagnosis, 17
- Brown recluse spider bites, vs. infections, 595, 636
- Brucella suis* infections, abscess, e129
- Brucellosis
 chronic hepatosplenic suppurative, 1024
 endocarditis in, skin lesions with, 63, 149
 in pregnancy, 1172
 treatment, 506
- BufferGel vaginal microbicide, safety, 476
- Burkholderia cepacia* infections, catheter-related, guidelines, 1249
- Burkholderia pseudomallei* infections
 in cystic fibrosis, e15
 epidemiology, Laos, 653
- Bursitis, septic, in pediatric patients, e102
- B virus infections, nosocomial, prevention, 446
- Campylobacter fetus* infections, in HIV infection, 295
- Campylobacter* infections, diarrhea
 epidemiology, 573
 practice guidelines, 331
- Campylobacter jejuni* infections
 epidemiology, 1201
 resistance in, 1201
 sulfonamides, 1608
 sepsis, in pediatric patients, e97
- Cancer
 Aspergillus infections in, mortality in, 358
 bacteremia in, due to venous access port, 1776
 breast, bone marrow or stem cell transplantation in, infectious complications, 391, 546
 Candida dubliniensis infections in, 1034
 Candida lusitanae infections in, 186
 candidemia in, outcome, 1713
 Cryptococcus neoformans infections in, e145
 fever in, imaging studies, 191
 due to human papillomavirus, in HIV infection, 611
 infectious causes, 675
 Legionella infections in, treatment failure, 1562
 liver, in hepatitis C, in HIV infection, 1207
 neutropenia in
 bacteremia breakthrough, antifungal prophylaxis and, 1532, 1538
 gram-negative bacteremia prediction in, 832
 treatment, in children, 36
 Salmonella infections in, 263
 Scedosporium prolificans infections in, e158
 Stenotrophomonas maltophilia infections in, susceptibility testing [letter], 1656
- Candida*, resistance to, 1554
- Candida albicans*, in vaginal flora, e69
- Candida albicans* infections
 bacteremia, venous port-related, 1776
 pathology, 1589
- Candida dubliniensis* infections, in cancer, 1034
- Candida* infections (candidiasis)
 in bone marrow or stem cell transplantation, 546
 catheter-related, guidelines, 1249
 endocarditis, literature review, 50
 in HIV infection, oropharyngeal, 1554
 osteomyelitis, vertebral, 527
 prophylaxis, in intensive care unit, 1191
 T lymphocyte type 1/type 2 immunity in, 76
 vaginitis, treatment with probiotics, 1567
- Candida lusitanae* infections, in cancer, 186

- Candidemia
 in cancer, outcome, 1713
 in neonates, systemic involvement, 1018
 nosocomial, costs [letter], 1100
 vertebral osteomyelitis in, 527
- Candiduria, nosocomial, review, 1602
- Carbapenems
 for intravascular catheter-related infections, 1249
 resistance to, new β -lactamases and, 1085
- Cardiac arrhythmias, fluoroquinolone-induced, 572
- Cardiomyopathy
 dilated, due to *Coxiella burnetii*, 1440
 in HIV infection, highly active antiretroviral therapy effects on, in pediatric patients, 464
- Cardiovascular disease, in HIV infection, 130
- Carditis, due to *Coxiella burnetii*, 1440
- Carriage (see Colonization)
- Case-control studies, drug resistance risk factors, methodological principles, 1055
- Case reports, editorial policy on, 1
- Catecholamines, in T lymphocyte type 1/type 2 immunity, 76
- Catheter-related infections
 urinary, due to *Candida*, 1602
 vascular
 after bone marrow or stem cell transplantation, 391, 546
 in cancer, 1776
 guidelines, 1249
 in HIV infection, 1776
- Cefaclor, resistance to, *Streptococcus pneumoniae*, S81
- Cefepime
 for intravascular catheter-related infections, 1249
 resistance to
Acinetobacter, S104
Pseudomonas aeruginosa, S146
- Cefixime
 for febrile neutropenia, in pediatric patients, 36
 for gonorrhea, 1313
 in HIV infection, 611
- Cefmenoxime, area under inhibitory concentration curve values, S39
- Cefotaxime
 resistance to, *Streptococcus pneumoniae*, 1463
 for *Vibrio cholerae* non-serogroup O:1 infections, e117
- Cefprozil, resistance to, *Streptococcus pneumoniae*, S81
- Ceftazidime
 for melioidosis, in cystic fibrosis, e15
 resistance to
Acinetobacter, S104
Escherichia coli, S94
Klebsiella pneumoniae, S94
Proteus mirabilis, S94
Pseudomonas aeruginosa, S146
Stenotrophomonas maltophilia, S104
- Ceftriaxone
 for diarrhea, 331
 for gonorrhea, in HIV infection, 611
 resistance to
Escherichia coli, S94
Klebsiella pneumoniae, S94
Proteus mirabilis, S94
 for syphilis, in HIV infection, 611
- Cefuroxime, resistance to, *Streptococcus pneumoniae*, S81, 1463
- Cellular immune response
 in cellulitis, e17
 T lymphocytes in, type 1/type 2 immunity, 76
- Cellulitis
 after bone marrow or stem cell transplantation, 391, 546
 cellular immunity in, e17
 due to β -hemolytic streptococci, laboratory tests for, e9
 due to *Vibrio cholerae* non-serogroup O:1, e117
- Cell wall, fluoroquinolone effects on, S9
- Centers for Disease Control and Prevention guidelines, pelvic inflammatory disease, 103
- Central nervous system (see Brain; Spinal cord)
- Cephalosporinases, new, antibiotic therapy selection and, 1085
- Cephalosporins (see also specific drugs)
 for intravascular catheter-related infections, 1249
 resistance to
 new β -lactamases and, 1085
Salmonella, 263
 for Whipple's disease, 457
- Cerebellar ataxia, in enterovirus 71 infections, 236
- Cerebritis, due to *Vibrio cholerae* non-serogroup O:1, e117
- Cerebrospinal fluid
 examination
 in chemical meningitis, 179
 in *Mycoplasma pneumoniae* encephalitis, 1674
 in syphilis, 611, 1661
 in toxoplasmosis, in stem cell transplantation, e1
 HIV in, after primary infection treatment, 1095
- Cervicitis, in HIV infection, screening for, 611
- Cervix, TT virus colonization, in pregnancy, 1376
- Cesarean delivery, toxic shock syndrome after, 1470
- CHAT poliomyelitis vaccine, HIV transmission hypothesis, 1068
- Chemical meningitis (see Aseptic meningitis)
- Chemokines and chemokine receptors, in HIV infection, in tuberculosis, 650
- Chemotherapy, *Bacillus cereus* infections after, in pediatric patients, 1456
- Chlamydia pneumoniae* infections
 pneumonia
 in Finland, 1141
 in pediatric patients, 1281
 resistance in, trimethoprim-sulfamethoxazole, 1608
- Chlamydia trachomatis* infections
 diagnosis, 103
 in HIV infection, 611, 808
 pelvic inflammatory disease, Centers for Disease Control and Prevention guidelines, 103
 resistance in, trimethoprim-sulfamethoxazole, 1608
 urethritis, 995
- Chloramphenicol
 for melioidosis, in cystic fibrosis, e15
 resistance to
Enterococcus, S133
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
Streptococcus pneumoniae, 1039
- Cholera, practice guidelines, 331
- Chorioretinitis
 due to *Candida*, in neonates, 1018
 due to *Treponema pallidum*, 1661
- Chromobacterium violaceum* sepsis, in pediatric patients, e107
- Chronic fatigue syndrome
 information resources for, 938
 treatment with antiviral agents [letter], 1657
- Chronic granulomatous disease, brain abscess in, due to *Aspergillus*, e137
- Chronic obstructive pulmonary disease, *Streptococcus pneumoniae* infections in, levofloxacin-resistant, 701
- Cidofovir
 for adenovirus infections, in stem cell transplantation, 1290
 for progressive multifocal leukoencephalopathy, failure, 150
 for respiratory papillomatosis, e62
- Ciprofloxacin

- area under inhibitory concentration curve values, S39
- for *Chromobacterium violaceum* sepsis, e107
- for diarrhea, 331
- excretion of, 822
- for gonorrhea
 - failure, 884
 - in HIV infection, 611
- for histoplasmosis, in HIV infection, 483
- mechanisms of action, S9
- resistance to, S1
 - Acinetobacter*, S104
 - Enterococcus*, S133
 - extended-spectrum β -lactamase-producing organisms, S94
 - Neisseria gonorrhoeae*, S133
 - Pseudomonas aeruginosa*, S146
 - Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114
 - Stenotrophomonas maltophilia*, S104
- toxicity, S72
 - for *Vibrio cholerae* non-serogroup O:1 infections, e117
- Cirrhosis, in hepatitis C
 - cryptococcosis with, myositis in, 1104
 - in HIV infection, 1207
- Clarithromycin
 - for *Mycobacterium avium* complex infections, prophylactic, in HIV infection, 1615
 - resistance to, *Streptococcus pneumoniae*, S81
 - for streptococcal pharyngitis, 1798
- Clinafloxacin
 - for febrile neutropenia, 381
 - pharmacodynamics, S39
 - resistance to, S1
- Clindamycin
 - for babesiosis, 1117
 - resistance to
 - Moraxella catarrhalis*, S81
 - Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114
 - Streptococcus pneumoniae*, S81
 - for toxoplasmosis, e1
- Clofazimine, for leprosy, 930
- Clostridium difficile* infections
 - colitis, after bone marrow or stem cell transplantation, 391
 - diarrhea, practice guidelines, 331
 - treatment, probiotics in, 1567
- Clostridium* infections, resistance in, trimethoprim-sulfamethoxazole, 1608
- Clostridium tertium* infections, bacteremia, 975
- Clotrimazole, prophylactic, in intensive care unit, 1191
- Coagulopathy, due to *Neisseria meningitidis*, protein C replacement in, 1338
- Coccidioidomycosis
 - pathology, 1589
 - risk factors for, 708
- Cognitive dysfunction, in *Mycoplasma pneumoniae* infections, e31
- Colitis, due to *Clostridium difficile*, after bone marrow or stem cell transplantation, 391
- Colonization
 - artificial fingernails
 - Candida*, 352
 - hand cleansing methods and, 367
 - Candida*
 - artificial nails, 352
 - vs. infection, 1602
 - enterococci, vancomycin-resistant
 - in hemodialysis, 23
 - prevention, 826
 - gram-negative organisms, in neonatal intensive care unit, 220
 - Mycobacterium*, nontuberculous, in cystic fibrosis, 1298
 - Mycobacterium abscessus*, in cystic fibrosis, 1648
 - pneumococci, antibiotic-resistant, in Asian children, 1463
 - Scedosporium prolificans*, e158
 - Staphylococcus aureus*, methicillin-resistant
 - after hospital discharge, 1393
 - viridans streptococci effects on, in newborns, 1399, 1408
 - Streptococcus pneumoniae*
 - levofloxacin-resistant, 701
 - in pediatric patients, Indonesia, 1039
 - TT virus, in pregnancy, 1376
 - vaginal, normal, e69
- Colony-stimulating factors, for HIV infection, 766
- Compression therapy, for chronic venous disease, 949
- Condylomata acuminata, due to human papillomavirus, in HIV infection, 611
- Confusion, due to *Toxoplasma gondii*, in stem cell transplantation, e1
- Congenital infections, due to *Candida*, 1579, 1637
- Conjunctivitis, in HIV infection, 1628
- Coronary angiography, *Corynebacterium jeikeium* endocarditis after, e120
- Corticosteroids
 - for cancer, candidemia due to, outcome, 1713
 - for herpes zoster, 1481
 - for HIV infection, 1738
 - spinal epidural lipomatosis due to, e90
 - for panhypopituitarism, infections related to, 153
 - Salmonella* infections related to, 263
 - in T lymphocyte type 1/type 2 immunity, 76
- Corynebacterium* infections, catheter-related, guidelines, 1249
- Corynebacterium jeikeium* infections, endocarditis, after coronary angiography, e120
- Costs (see Economic issues)
- Co-trimoxazole (see Trimethoprim-sulfamethoxazole)
- Cough, persistent, in pertussis, 1691, 1698
- Coxiella burnetii* infections
 - myocarditis, 1440
 - nosocomial, prevention, 446
 - review, 897
- Creutzfeldt-Jacob disease
 - prevention, disinfection and sterilization for, 1348
 - variant, clinical implications, 1726
- Crimean-Congo hemorrhagic fever, nosocomial, prevention, 446
- Critical illness, human herpesvirus type 6 reactivation in, 197
- Crohn's disease, *Clostridium tertium* bacteremia in, 975
- Croup, due to adenovirus, in Korean children, 1423
- Cryptococcus neoformans* infections
 - in cancer, e145
 - in hepatitis C, myositis in, 1104
 - in HIV infection, antigen detection in, false-negative results in, 836
 - myelitis, 1235
 - pathology, 1589
- Cryptosporidiosis
 - practice guidelines, 331
 - treatment with paromomycin [letter and reply], 1516, 1517
- Culture
 - blood
 - for bacteremia
 - occult, 559
 - usefulness, 1651
 - for pneumonia, vs. lung tap, 715
 - intravascular catheter-related infections, 1249
 - Mycobacterium tuberculosis*, in pediatric patients, 17
 - stool, in diarrhea, 331
- Cushing's syndrome, due to corticosteroids, spinal epidural lipomatosis in, e90
- Cyclosporiasis, practice guidelines, 331

- Cyclosporine, for HIV infection, 1738
- Cystic fibrosis
Burkholderia pseudomallei infections in, e15
Mycobacterium abscessus colonization in, 1648
nontuberculous mycobacterial infections in, 1298
- Cystitis
due to adenovirus, in bone marrow transplantation, 871, 1325
due to *Candida*, 1602
- Cytokines
for HIV infection, 766, 1738, 1756
T lymphocyte type 1/type 2 immunity and, 76
- Cytology, in infection diagnosis, 1589
- Cytomegalovirus infections
chronic fatigue syndrome in [letter], 1657
diagnosis, 596
disseminated, without HIV infection or transplantation, 313
in HIV infection
antibiotic prophylaxis for, 116
preemptive treatment vs. prophylaxis, 783
retinitis, 815
pathology, 1589
pneumonia, in leukemia, 539
recurrent, in multiple organ failure syndrome, 197
retinitis
in HIV infection, Current News, May 1
after stem cell transplantation, 214
thrombosis in, 983
in transplantation
preemptive treatment vs. prophylaxis, 742
prevention, 596
- Dapsone
for leprosy, 930
for *Mycobacterium avium* complex infections, prophylactic, in HIV infection, 1615
- Darier's disease, *Staphylococcus aureus* intracellular persistence in, 1643
- Databases, for travel medicine, 757
- Debridement, infected hip arthroplasty, 419
- Decision-making, in simulated bioterrorist attack, 436
- Dengue hemorrhagic fever
microvascular leakage in, noninvasive measurement, 243
reemergence, 675
treatment, 204
- Dermacentor* species, review, 897
- Desipramine, for herpes zoster, 1481
- Diabetes mellitus
alternariosis in, 1178
coccidioidomycosis risk in, 708
ketoacidosis in, infection as trigger, 30
Salmonella infections in, 263
- Diarrhea
bloody, epidemiology, 573
due to *Campylobacter jejuni*, epidemiology, 1201
due to *Clostridium difficile*, treatment, probiotics in, 1567
due to enteroaggregative *Escherichia coli*, in travelers, 1706, 1710
infectious, practice guidelines for, 331
due to rotavirus, severity, vs. viral strain, 1126
due to *Tropheryma whippelii*, 457
- Didanosine, for HIV infection
ototoxicity, 1623
resistance to, monitoring, 774
- Dihydrofolate, inhibition, trimethoprim-sulfamethoxazole in, 1608
- Disinfection, Creutzfeldt-Jacob disease prevention, 1348
- Diskitis, due to *Candida*, after spinal surgery, 352
- Disseminated intravascular coagulation
in babesiosis, 1117
in *Neisseria meningitidis* infections, protein C replacement in, 1338
- DNA, synthesis, fluoroquinolone effects on, S9
- DNA analysis
for microorganisms in global resistance surveillance program, S156
for *Pneumocystis carinii*, in immunocompetent infants, 855
for tickborne diseases, 897
- DNA gyrase, inhibition, fluoroquinolones in, S9
- Doxycycline
for brucellosis, 1024
for cholera, 331
for Lyme disease, 897
for melioidosis, in cystic fibrosis, e15
resistance to, *Enterococcus*, S133
for *Rickettsia* infections, 897
- Drug abuse, injection
hepatitis B vaccination in, e143
Staphylococcus aureus infections in, 581
- Drug interactions, book reviews, 1245
- Drug resistance (see also Susceptibility testing)
Abiotrophia, e140
Acinetobacter, global, S94, S156
acyclovir, herpes simplex virus, 611
albendazole, *Giardia lamblia*, 1792
amikacin, 1162
Acinetobacter, S104
Pseudomonas aeruginosa, S146
Stenotrophomonas maltophilia, S104
amoxicillin, *Haemophilus influenzae*, S81
ampicillin, *Enterococcus*, S133
azithromycin, *Streptococcus pneumoniae*, S81
aztreonam, *Pseudomonas aeruginosa*, S146
Campylobacter fetus, 295
Campylobacter jejuni, 1201
Candida, 1554
carbapenems, new β -lactamases and, 1085
cefalor, *Streptococcus pneumoniae*, S81
cefepime
Acinetobacter, S104
Pseudomonas aeruginosa, S146
cefotaxime, *Streptococcus pneumoniae*, 1463
cefprozil, *Streptococcus pneumoniae*, S81
ceftazidime
Acinetobacter, S104
Pseudomonas aeruginosa, S146
Stenotrophomonas maltophilia, S104
cefuroxime, *Streptococcus pneumoniae*, S81, 1463
cephalosporins
new β -lactamases and, 1085
Salmonella, 263
- chloramphenicol
Enterococcus, S133
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
Streptococcus pneumoniae, S81, 1039
- ciprofloxacin
Acinetobacter, S104
Enterococcus, S133
Neisseria gonorrhoeae, 1313
Pseudomonas aeruginosa, S146
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
Stenotrophomonas maltophilia, S104
- clarithromycin, *Streptococcus pneumoniae*, S81
- clindamycin
Moraxella catarrhalis, S81
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
Streptococcus pneumoniae, S81

- coresistance patterns, global studies, S94
- cross-resistance, in quinolones, S1
- dichotomous, in quinolones, S1
- doxycycline, *Enterococcus*, S133
- Enterobacteriaceae, global, S94, S156
- enterococci, vancomycin, in hemodialysis, 23
- Enterococcus*
- global, S133, S156
 - quinupristin-dalfopristin, coresistance patterns, S133
 - vancomycin, 826, 1373, 1381
 - bacteremia outcome and [letter and reply], 1110, 1112
 - coresistance patterns, S133
- erythromycin
- Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114
 - Streptococcus pneumoniae*, S81
- Escherichia coli*
- extended-spectrum β -lactamase-producing, 1162
 - global, S94, S156
 - quinolones, S1
- extended-spectrum β -lactamase-producing organisms, global, S94, S156
- fluconazole, *Candida*, 1554
- fluoroquinolones, 162
- Salmonella*, 263
 - theory, S39
- ganciclovir, in transplantation, 742
- gatifloxacin
- Acinetobacter*, S104
 - Enterococcus*, S133
 - Pseudomonas aeruginosa*, S146
 - Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114
 - Stenotrophomonas maltophilia*, S104
- gentamicin, 1162
- Acinetobacter*, S104
 - Enterococcus*, S133
 - Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114
- Giardia lamblia*, 1792
- global context, 675 (see also SENTRY Antimicrobial Surveillance Program)
- gram-negative organisms
- antibiotic therapy selection and, 1085
 - fluoroquinolones, 162
 - global, S156
- Haemophilus influenzae*, global, S81
- herpes simplex virus, acyclovir, 611
- HIV, monitoring, 774
- imipenem, 1162
- Pseudomonas aeruginosa*, S146
 - Streptococcus pneumoniae*, 1463
- ketoconazole, *Candida*, 1554
- Klebsiella pneumoniae*
- extended-spectrum β -lactamase-producing, 1162
 - global, S94, S156
- β -lactamase-producing organisms
- antibiotic therapy selection and, 1085
 - extended-spectrum, S94, S156
- levofloxacin, 1162
- Pseudomonas aeruginosa*, S146
 - Streptococcus pneumoniae*, 701
- loracarbef, *Streptococcus pneumoniae*, S81
- mechanisms, in quinolones, S1
- meropenem
- Acinetobacter*, S104
 - Pseudomonas aeruginosa*, S146
 - methicillin, *Staphylococcus aureus* (see *Staphylococcus aureus* infections, methicillin-resistant)
 - metronidazole, *Giardia lamblia*, 1792
 - monitoring, clinical microbiology laboratory services in, 604, 605
 - monobactams, new β -lactamases and, 1085
 - Moraxella catarrhalis*, global, S81
 - moxifloxacin, S16, S51
 - multiple
 - global surveillance for, method in, S156
 - Streptococcus pneumoniae*, 1463
 - tuberculosis, 373
 - Neisseria gonorrhoeae*
 - ciprofloxacin, S131
 - fluoroquinolones, 884
 - nitrofurantoin, *Enterococcus*, S133
 - ofloxacin, 1162
 - Pantoea agglomerans*, fluoroquinolones, 162
 - penicillin
 - Moraxella catarrhalis*, S81
 - new β -lactamases and, 1085
 - Streptococcus pneumoniae*, S22, S81, 972, 1044
 - pharmacodynamic studies, S39
 - piperacillin
 - Acinetobacter*, S104
 - Pseudomonas aeruginosa*, S146
 - piperacillin-tazobactam
 - Acinetobacter*, S104
 - Pseudomonas aeruginosa*, S146
 - Stenotrophomonas maltophilia*, S104
 - Proteus mirabilis*, S94
 - Pseudomonas aeruginosa*
 - fluoroquinolones, 162
 - global, S146, S156
 - quinolones, S1
 - quinupristin-dalfopristin, *Enterococcus*, coresistance patterns, S133
 - rifampin
 - Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114
 - risk factors for, case-control studies, methodological principles, 1055
 - Salmonella*
 - global, S94
 - nontyphoidal, 263
 - Staphylococcus*, global, S114
 - Staphylococcus aureus*
 - methicillin (see *Staphylococcus aureus* infections, methicillin-resistant)
 - quinolones, S1
 - teicoplanin, 108
 - vancomycin, 108
 - Stenotrophomonas maltophilia*, 1656 [letter]
 - global, S104, S156
 - Streptococcus pneumoniae*, 1039, 1463
 - fluoroquinolones, S39
 - global, S81, S156
 - levofloxacin, 701
 - penicillin, S22, 972, 1044
 - quinolones, S1
 - vancomycin, 552
 - streptomycin, *Enterococcus*, S133
 - sulfamethoxazole, *Streptococcus pneumoniae*, 1039
 - sulfonamides, 1608
 - teicoplanin, *Staphylococcus aureus*, 108
 - tetracycline, 1162
 - Acinetobacter*, S104
 - Staphylococcus*, coagulase-negative, S114

- Staphylococcus aureus*, S114
Stenotrophomonas maltophilia, S104
Streptococcus pneumoniae, S81
ticarcillin, *Acinetobacter*, S104
ticarcillin-clavulanate
Acinetobacter, S104
Stenotrophomonas maltophilia, S104
tobramycin, 1162
Acinetobacter, S104
Pseudomonas aeruginosa, S146
Stenotrophomonas maltophilia, S104
trimethoprim-sulfamethoxazole, 1162, 1608
Enterococcus, S133
Haemophilus influenzae, S81
Staphylococcus, coagulase-negative, S114
Staphylococcus aureus, S114
Streptococcus pneumoniae, S81
trovafloxacin
Acinetobacter, S104
Pseudomonas aeruginosa, S146
Stenotrophomonas maltophilia, S104
tuberculosis, 159
multiple, clinical outcome, 373
use patterns and, 1189
vancomycin
Enterococcus, 826, 1373, 1381
bacteremia outcome and [letter and reply], 1110, 1112
coresistance patterns, S133
in hemodialysis, 23
Moraxella catarrhalis, S81
Staphylococcus aureus, 108
Streptococcus pneumoniae, 552
Dyspnea, in babesiosis, 1117
Ebola virus infections, nosocomial, prevention, 446
Echocardiography, in fungal endocarditis, 50
Economic issues
chronic venous disease, 949
cytomegalovirus infection prophylaxis, in HIV infection, 783
fellowship training on, adequacy of, 255
hip arthroplasty infections, 419
kidney failure in amphotericin B therapy, 686
nosocomial candidiasis [letter], 1100
pneumonia practice guidelines, 728
Eczema herpeticum, diagnosis, 1480, 1500
Editorials, case report policy, 1
Education
fellowship training survey, 255
in infectious disease, 752, 755
medical, clinical microbiology laboratory services in, 604, 605
patient, on infectious diarrhea prevention, 331
Edwardsiella tarda infections, myonecrosis, 1430
Efavirenz, resistance to, monitoring, 774
Eggs, *Salmonella enteritidis* infections due to, 890
Ehrlichiosis
hematologic counts during, 862
as nonspecific fever cause, 1434
review, 897
Elderly persons
coccidioidomycosis in, 708
herpes zoster in, 1481
hip arthroplasty infections in, treatment, 419
Streptococcus pneumoniae infections in, levofloxacin-resistant, 701
Electronic mail conference, on emerging infections, 270
Electrophores, pulsed-field gel, for microorganisms in global resistance surveillance program, S156
ELISA (see Enzyme-linked immunosorbent assay)
Emboli, in fungal endocarditis, 50
Emergency department
bacteremia diagnosis in, 559
blood diarrhea etiology in, 573
Chlamydia trachomatis infection diagnosis in, 103
gonorrhea diagnosis in, 103
pathologic studies in, 1589
Emerging infections
clinical microbiology laboratory services and, 604, 605
electronic mail conference and web page, 270
global context, 675
Whipple's disease, 457
Encephalitis
due to herpes simplex virus, vs. neurosyphilis, 1108
due to measles virus, in HIV infection, e57
due to *Mycoplasma pneumoniae*, in pediatric patients, 1674
due to sandfly fever virus serotype Toscana, 1241
subacute sclerosing, in American-born adult, 173
due to West Nile virus, outbreaks, New York City, 277
Encephalopathy
in HIV infection, 1487
Highly active antiretroviral therapy effects on, in pediatric patients, 464
spongiform
clinical implications, 1726
prevention, disinfection and sterilization for, 1348
Endocarditis
due to *Brucella*, skin lesions with, 63, 149
due to *Corynebacterium jeikeium*, after coronary angiography, e120
due to *Enterococcus*, vancomycin-resistant, treatment, 1373
due to fungi, literature review, 50
intravascular catheter-related, 1249
due to *Nocardia asteroides*, 660
prosthetic valve, due to *Staphylococcus hemolyticus*, e100
due to *Salmonella*, 263
due to *Staphylococcus aureus*, methicillin-resistant, in injection drug users, 581
due to *Streptococcus pneumoniae*, penicillin-resistant, 972
Endometritis
due to *Staphylococcus aureus*, toxic shock syndrome in, 1470
treatment, Centers for Disease Control and Prevention guidelines, 103
Endophthalmitis, due to *Candida*, in neonates, 1018
Energy balance, in HIV infection, 1769
Entamoeba histolytica infections, diarrhea, practice guidelines, 331
Enterobacter cloacae infections, bacteremia, venous port-related, 1776
Enterobacteriaceae infections
bacteremia, emergency room management, 559
resistance in, global, S94, S156
Enterobacter infections, catheter-related, guidelines, 1249
Enterococcus casseliflavus/flavescens infections, bacteremia, 1540
Enterococcus faecium, as probiotic, 1381
Enterococcus faecium infections, resistance in, vancomycin, 1381
Enterococcus gallinarum infections, bacteremia, 1540
Enterococcus infections
bacteremia, mortality in, 587
catheter-related, guidelines, 1249
resistance in
global, S133, S156
quinupristin-dalfopristin, coresistance patterns, S133
vancomycin, 1381
bacteremia outcome and [letter and reply], 1110, 1112
coresistance patterns, S133
in hemodialysis, 23
prevention, 826
treatment, 1373

- Enterotoxins, staphylococcal, e53
 toxic shock syndrome due to, 1470
- Enterovirus infections, treatment with pleconaril, e13, 228
- Enterovirus 71 infections, neurological manifestations, in pediatric patients, 236
- Envenomation, spider, vs. infection, 595, 636
- Enzyme immunoassays, for *Toxoplasma gondii*, in schizophrenia, 842
- Enzyme-linked immunosorbent assay
Gnathostoma spinigerum, e154
 as independent test [letter], 1114
Pneumocystis carinii, in immunocompetent infants, 855
Toxocara, e111
- Eosinophilia, in paragonimiasis, e171
- Epidemic typhus, meningitis in, 979
- Epidemiology (see also Outbreaks)
 adenovirus respiratory infections, in Korean children, 1423
 bacteremia, occult, 559
 basidiobolomycosis, gastrointestinal, Arizona, 1448
Campylobacter jejuni infections, 1201
 chronic venous disease, 949
 Creutzfeldt-Jacob disease, 1348
 cyclosporiasis, Missouri, 1010
 diarrhea, 331
 bloody, 573
Enterococcus casseliflavus/flavescens bacteremia, 1540
Enterococcus gallinarum bacteremia, 1540
 global context, 675
Helicobacter pylori infections, breast-feeding practices and, 1387
 herpes zoster, in elderly persons, 1481
 HIV infection
 East Timor, 991
 Thailand, 955
 influenza, Current News, May 1
 intravascular catheter-related infections, 1249
 leprosy, in United States immigrants, 930
 malaria, Georgia, e124
 melioidosis, Laos, 653
 meningitis, in pediatric patients, in Africa, 64
Neisseria meningitidis infections, in pediatric patients, in Massachusetts, 1004
 pertussis, in elderly persons [letter], 847
 pneumonia, Finland, 1141
 prion diseases, 1726
Salmonella enteritidis infections, phage type 4, Caribbean, 890
 sexually transmitted diseases, travelers' risk and, 1063
Staphylococcus aureus, vancomycin-resistant, 108
 tickborne diseases, 897
 travel diseases, information resources for, 757
 tuberculin test reactivity, in hospital physicians, 1331
 tuberculosis, Internet resources on, 1580
 West Nile viral encephalitis, New York City, 277
 zoonotic diseases, nosocomial, 446
- Epidural abscess, spinal, in pediatric patients, 9
- Epsilon-Barr virus infections, chronic fatigue syndrome in [letter], 1657
- Errata
 aspergillosis (2000;31:1524), 673
 CHAT oral polio vaccine (2001;32:1068), 1386
 chronic fatigue syndrome and fibromyalgia, resources for (2001;32:938), 1803
 cryptococcoma (2000;31:1303), 175
 cryptosporidiosis, paramomycin in (2001;32:1516), 1803
 cutaneous larva migrans (2000;31:493), 523
 disseminated *Mycobacterium avium* infection, treatment of (2000;31:1245), 1386
 foodborne listeriosis (2000;31:770), 1803
 levofloxacin-resistant *Streptococcus pneumoniae* (2001;32:701), 1247
Mycobacterium avium infection treatment (2000;31:1245), 1386
 nasal carriage or organisms (2000;31:875), 176
 protein C replacement, in severe meningococemia (2001;32:1338), 1803
 strongyloidiasis (2000;31:e5), 176
 toxoplasmosis (2001;32:842), 1247
- Erythema nodosum leprosum, in immigrants, 930
- Erythromycin
 for *Campylobacter jejuni* infections, 1201
 for diarrhea, 331
 resistance to
 Staphylococcus, coagulase-negative, S114
 Staphylococcus aureus, S114
- Erythropoietin, for HIV infection, 766
- Escherichia coli*, in vaginal flora, e69
- Escherichia coli* infections
 catheter-related, guidelines, 1249
 diabetic ketoacidosis in, 30
 diarrhea
 epidemiology, 573
 practice guidelines, 331
 enteroaggregative, in travelers' diarrhea, 1706, 1710
 O157:H7, diarrhea, epidemiology, 573
 pneumonia, lung tap for, 715
 resistance in
 extended-spectrum β -lactamase-producing, 1162
 global, S94, S156
 quinolones, S1
 sulfonamides, 1608
 trimethoprim-sulfamethoxazole, 1608
- Shiga toxin-producing
 diarrhea, epidemiology, 573
 testing for [letter], 1517
- T lymphocyte type 1/type 2 immunity in, 76
- virulence factors, in urinary tract infections, 1523
- Estrogens, in T lymphocyte type 1/type 2 immunity, 76
- Ethambutol, for *Mycobacterium avium* complex infections, 1547
- Ethical issues, in fellowship acceptance, 752, 755
- Ethnic factors
 in coccidioidomycosis susceptibility, 708
 in *Helicobacter pylori* infection epidemiology, 1387
 in *Streptococcus pneumoniae* infections, in HIV infection, 794
- EuroQol Group questionnaire, in HIV infection quality-of-life measurement, e47
- Exercise, in HIV infection, 1769
- Eye infections
 due to *Candida*, in neonates, 1018
 due to cytomegalovirus, after stem cell transplantation, 214
 due to *Treponema pallidum*, 1661
- Famciclovir
 for herpes simplex virus infections, in HIV infection, 611
 for herpes zoster, 1481
- Fasciitis, necrotizing, due to β -hemolytic streptococci, laboratory tests for, e9
- Fasciola hepatica* infections, liver, 727, 820, 1658 [letter]
- Fat, body, distribution of, in HIV infection, 130
- Fatigue, chronic
 information resources for, 938
 treatment with antiviral agents [letter], 1657
- Fat redistribution, due to HIV therapy, 1769
- Fellowship programs
 in infectious disease, 752, 755
 survey of recent graduates, 255
- Ferritin, as HIV severity marker, 1496

- Fever
- blackwater, in malaria, 1133
 - dengue hemorrhagic
 - microvascular leakage in, noninvasive measurement, 243
 - treatment, 204
 - interval of, in meningitis, in pediatric patients, 566
 - in malaria, treatment, 838
 - Mediterranean spotted, review, 897
 - meningococcal vaccines, 1273
 - in neutropenia
 - in cancer
 - gram-negative bacteremia prediction in, 832
 - treatment, in children, 36
 - empirical antifungal therapy for [letter and reply], 320, 518
 - treatment, 381
 - in occult bacteremia, emergency department management, 559
 - relapsing, review, 897
 - of unknown origin
 - positron emission tomography in, 191
 - tickborne infections in, 1434
- Fibromyalgia, information resources for, 938
- Finger(s), acrodermatitis continua of Hallopeau, 431, 505
- Fluconazole
- for *Candida lusitanae* infections, 186
 - for *Cryptococcus neoformans* infections, in cancer, e145
 - for fever, in neutropenia [letter and reply], 320, 518
 - for histoplasmosis, in HIV infection, 483
 - for intravascular catheter-related infections, 1249
 - for osteomyelitis, due to *Candida*, 527
 - prophylactic
 - in intensive care unit, 1191
 - for neutropenia, bacteremia breakthrough in, 1532, 1538
 - resistance to, *Candida*, 1554
 - for urinary tract infections, due to *Candida*, 1602
- Flucytosine
- for endocarditis, 50
 - for osteomyelitis, due to *Candida*, 527
- Fluid therapy, for dengue hemorrhagic fever, 204
- Flukes, liver, 727, 820
- Fluorescent antibody staining, for herpes simplex virus, in HIV infection, 611
- Fluoro-deoxyglucose, fluorine-labeled, in positron emission tomography, in fever of unknown origin, 191
- Fluoroquinolones
- for diarrhea, 331
 - for intravascular catheter-related infections, 1249
 - mechanisms of action, S9
 - resistance to, 162
 - cross-resistance and dichotomous, S1
 - Neisseria gonorrhoeae*, 884
 - Salmonella*, 263
 - for respiratory infections, S64
 - toxicity, S72
- Foodborne diseases
- due to *Campylobacter jejuni*, epidemiology, 1201
 - clinical microbiology laboratory services and, 604, 605
 - due to *Cyclospora*, outbreaks, 1010
 - diarrhea in, practice guidelines, 331
 - due to *Gongylonema*, 1378
 - due to *Listeria monocytogenes*, treatment [letter and reply], 1518, 1519
 - due to *Salmonella*, nontyphoidal, 263
 - due to *Salmonella enteritidis*, phage type 4, 890
 - trichinosis
 - T lymphocyte type 1/type 2 immunity in, 76
 - treatment failure, 638
- Foscarnet
- for cytomegalovirus infections, retinitis, 214
 - for herpes simplex virus, in HIV infection, 611
- Francisella tularensis* infections, review, 897
- Fungal infections (see also specific infections)
- catheter-related, guidelines, 1249
 - endocarditis, literature review, 50
 - invasive, in bone marrow transplantation, 1319
 - in neutropenia, empirical antifungal therapy for [letter and reply], 320, 518
 - pathology, 1589
 - prophylaxis
 - in intensive care unit, 1191
 - in neutropenia, bacteremia breakthrough and, 1532, 1538
 - T lymphocyte type 1/type 2 immunity in, 76
 - treatment, guidelines for [letter], 321
- Fungemia
- due to *Candida*, in neonates, 1018
 - due to *Candida lusitanae*, 186
- Fusarium* infections, in heart-liver transplantation, 1237
- Fusobacterium nucleatum* infections, liver abscess, in lymphocytopenia [letter], 326
- Gabapentin, for herpes zoster, 1481
- Gallium scintigraphy, in fever of unknown origin, 191
- Ganciclovir
- for chronic fatigue syndrome [letter], 1657
 - for cytomegalovirus infections, 313
 - prophylactic, 596
 - retinitis, 214
 - in transplantation, 742
 - resistance to, in transplantation, 742
- Gardnerella vaginalis*, in normal flora, e69
- Gastrointestinal infections
- due to *Basidiobolus*, 1448
 - due to *Campylobacter fetus*, in HIV infection, 295
 - due to *Campylobacter jejuni*, epidemiology, 1201
 - due to *Histoplasma capsulatum*, in HIV infection, 483
 - practice guidelines, 331
 - due to rotavirus, severity, vs. viral strain, 1126
 - due to *Salmonella*, nontyphoidal, 263
 - due to *Tropheryma whippelii*, 457
- Gastrointestinal tract
- bleeding in, in HIV infection, 1487
 - fluoroquinolone-resistant bacteria in, 162
 - fluoroquinolone toxicity to, S72
- Gatifloxacin
- mechanisms of action, S9
 - pharmacodynamics, S39
 - resistance to
 - Acinetobacter*, S104
 - Enterococcus*, S133
 - Pseudomonas aeruginosa*, S146
 - Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114
 - Stenotrophomonas maltophilia*, S104
- Gel, alcohol-based, for hand cleansing, artificial fingernail colonization and, 367
- Genetic factors, in infections, 675
- Genital tract infections
- due to herpes simplex virus, in HIV infection, 611
 - in HIV infection, 611
 - due to *Mycobacterium tuberculosis*, after kidney transplantation, 662
 - due to *Staphylococcus aureus*, toxic shock syndrome in, 1470
 - upper, treatment, Centers for Disease Control and Prevention guidelines, 103
- Genotyping, in drug resistance detection, in HIV infection, 774

- Gentamicin
 - for brucellosis, 506
 - for intravascular catheter-related infections, 1249
 - resistance to, 1162
 - Acinetobacter*, S104
 - Enterococcus*, S133
 - extended-spectrum β -lactamase-producing organisms, S94
 - Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114
 - for tuberculosis, refractory, 44
- Geriatric patients (see Elderly persons)
- Giant cell pneumonia, due to measles virus, in HIV infection, e57
- Giardiasis
 - in HIV infection, 1792
 - practice guidelines, 331
- Global Infectious Disease and Epidemiology Network, for travel medicine information, 757
- Global view, of infectious diseases, 675
- Glomerulonephritis, in parvovirus B19 infections, 167
- Gloves, for vancomycin-resistant *Enterococcus* control, 826
- Glucose, metabolism of, in HIV infection, 130
- Gnathostomiasis, medullary, e154
- Gongylonema* infections, oral cavity, 1378
- Gonococcal infections (see *Neisseria gonorrhoeae* infections)
- Good's syndrome, adult-onset [letter], 323
- Gram-negative infections
 - area under inhibitory concentration curve values, S39
 - resistance in, 1085
 - fluoroquinolones, 162
 - global, S156
- Gram-positive infections
 - area under inhibitory concentration curve values, S39
 - moxifloxacin for, S16
- Gram stain, for infection diagnosis, 1589
- Granulocyte colony-stimulating factor, for HIV infection, 766, 1738
- Granulocyte-macrophage colony-stimulating factor
 - for HIV infection, 766, 1738
 - for rhinocerebral zygomycosis, e166
- Granulomas, pathology, 1589
- Grepafloxacin
 - resistance to, S1
 - toxicity, S72
- Guidelines
 - development, 851
 - fungal infections [letter], 321
 - infectious diarrhea, 331
 - intravascular catheter-related infections, 1249
 - pelvic inflammatory disease, 103
 - penicillin skin testing, 1685
 - pneumonia, cost-effectiveness, 728
- Guillain-Barré syndrome
 - due to *Campylobacter jejuni*, 1201
 - due to enterovirus 71, 236
 - due to meningococcal vaccines, 1273
- HAART (see Highly active antiretroviral therapy)
- Haemaphysalis* species, review, 897
- Haemophilus aphrophilus*, misidentification [letter and reply], 987, 989
- Haemophilus influenzae*, in vaginal flora, e69
- Haemophilus influenzae* infections
 - epidemiology, in pediatric patients, in Africa, 64
 - fever interval in, in pediatric patients, 566
 - pneumonia
 - in Finland, 1141
 - lung tap for, 715
 - resistance in
 - global, S81
 - trimethoprim-sulfamethoxazole, 1608
- T lymphocyte type 1/type 2 immunity in, 76
- treatment, moxifloxacin, S51, S64
- vaccination
 - antibody measurement after, 2
 - failure, 1700
- Hallopeau, acrodermatitis continua of, digital, 431, 505
- Halofantrine, blackwater fever due to, 1133
- Hand cleansing methods, artificial fingernail colonization and, 367
- Hantavirus infections, nosocomial, prevention, 446
- Headache, meningococcal vaccines, 1273
- Hearing loss, nucleoside analog reverse transcriptase inhibitors, 1623
- Heart (see also Endocarditis)
 - candidiasis, in neonates, 1018
 - failure
 - in babesiosis, 1117
 - in HIV infection, 1487
 - fluoroquinolone effects on, S72
 - myocarditis, due to *Coxiella burnetii*, 1440
 - Q fever effects on, 1440
 - transplantation
 - cytomegalovirus infections in, prevention, 742
 - pneumococcal vaccination in, 307
- Heart-liver transplantation, *Fusarium* infections in, 1237
- Helicobacter pylori* infections
 - asymptomatic, breast-feeding practices and, 1387
 - pathology, 1589
 - resistance in, sulfonamides, 1608
- Helminthic infections, T lymphocyte type 1/type 2 immunity in, 76
- Hematoxylin and eosin stain, for infection diagnosis, 1589
- Hemodialysis
 - catheter-related infections in, guidelines, 1249
 - vancomycin-resistant organism acquisition in
 - Enterococcus*, 23
 - Staphylococcus aureus*, 108
- Hemoglobin
 - as HIV severity marker, 1496
 - measurement, in ehrlichiosis, 862
- Hemoglobinuria, in malaria, 1133
- Hemolysis, in malaria, 1133
- Hemolytic uremic syndrome, Shiga toxin testing in [letter], 1517
- Hemorrhagic cystitis, in bone marrow transplantation, due to adenovirus, 1325
- Hemorrhagic fever
 - dengue
 - microvascular leakage in, noninvasive measurement, 243
 - treatment, 204
 - nosocomial, prevention, 446
- Hepatitis, T lymphocyte type 1/type 2 immunity in, 76
- Hepatitis A
 - in HIV infection, 297
 - vaccination
 - boosters, 396
 - in liver transplantation [letter], 1656
- Hepatitis B
 - in HIV infection, reactivation, 144
 - vaccination
 - in injection drug users, e143
 - in travelers, 1063
- Hepatitis C
 - cryptococcosis with, myositis in, 1104
 - hepatopulmonary syndrome in, treatment, e131
 - in HIV infection
 - lamivudine effects on, 963
 - mortality in, 492, 1207

- treatment, amantadine, 830
- Hepatocellular carcinoma, in hepatitis C, in HIV infection, 1207
- Hepatopulmonary syndrome, treatment, e131
- Herpes simplex virus infections
 - in bone marrow or stem cell transplantation, 546
 - encephalitis, vs. neurosyphilis, 1108
 - as histoplasmosis risk factor, in HIV infection, 1215
 - in HIV infection, 611
 - pathology, 1589
 - resistance in, acyclovir, 611
 - skin manifestations, 1480, 1500
- Herpes zoster
 - in elderly persons, 1481
 - after stem cell transplantation, 1414
- Highly active antiretroviral therapy, for HIV infection
 - hepatitis B reactivation in, 144
 - immune response in, 1738
 - leishmaniasis and, 633
 - measles vaccination response, 1090
 - nutrition and, 1769
 - parvovirus B19-induced anemia resolution in, e122, 1361
 - in pediatric patients, 464
- Hip arthroplasty, infections, treatment, 419
- Histiocytosis, due to *Campylobacter fetus*, in HIV infection, 295
- Histoplasmosis
 - endocarditis in, literature review, 50
 - in HIV infection
 - gastrointestinal, 483
 - risk factors for, 1215
 - pathology, 1589
- HIV infection (see Human immunodeficiency virus infection)
- Human granulocytic ehrlichiosis
 - hematologic counts during, 862
 - as nonspecific fever cause, 1434
 - review, 897
- Human herpesvirus type 6 infections
 - recurrent, in multiple organ failure syndrome, 197
 - in transplantation, 1357
- Human herpesvirus type 7 infections, in transplantation, 1357
- Human herpesvirus type 8 infections
 - in kidney allografts, Kaposi's sarcoma development, 1502
 - sarcoidosis and, 1100
- Human immunodeficiency virus infection
 - acute (see Human immunodeficiency virus infection, primary)
 - antibodies in, 1756
 - Aspergillus* infections in, mortality in, 358
 - avascular necrosis in, 1221
 - bacteremia in, due to venous access port, 1776
 - Campylobacter fetus* infection in, 295
 - Candida dubliniensis* infections in, 1034
 - candidiasis in, oropharyngeal, 1554
 - cardiovascular risks in, 130
 - Chlamydia trachomatis* infections in, 611
 - screening for, 808
 - clinical features, in Thailand, 955
 - cryptococcosis in
 - antigen detection in, false-negative results in, 836
 - meningitis, 955
 - myelitis, 1235
 - cytomegalovirus infections in
 - antibiotic prophylaxis for, 116
 - retinitis, 815
 - treatment, Current News, May 1
 - dual *Pneumocystis carinii* infection and tuberculosis in, 289
 - epidemiology, 675
 - East Timor, 991
 - Thailand, 955
 - giardiasis in, 1792
 - gonorrhea in, 611
 - hepatitis A in, 297
 - hepatitis B in, reactivation, 144
 - hepatitis C in
 - lamivudine effects on, 963
 - mortality in, 492
 - herpes simplex virus infections in, 611
 - histoplasmosis in
 - gastrointestinal, 483
 - risk factors for, 1215
 - immunopathogenesis, 1738
 - influenza in
 - outbreaks, 1784
 - progression after, 1366
 - Kawasaki-like syndromes in, 1628
 - leishmaniasis in, highly active antiretroviral therapy effects on, 633
 - lipodystrophy in, 130
 - liver disease in, mortality in, 492
 - lymphoma in, acyclovir and [letter], 989
 - measles in, e57
 - meningitis in, due to *Cryptococcus neoformans*, 836, 955
 - metabolic abnormalities in, 130
 - mortality, changing spectrum, 1487
 - Mycobacterium abscessus* infections in, 432
 - Mycobacterium avium* complex infections in
 - antibiotic prophylaxis for, 116
 - prophylaxis, 1615
 - treatment, e81
 - Mycoplasma genitalium* infections in, 611
 - myelitis in, due to *Cryptococcus neoformans*, 1235
 - neutropenia in, natural history, 469
 - new infections in, 432
 - non-B subtype
 - transmission by travelers, 1732
 - virus load measurement in, 1227
 - nonprogression, natural history, 1756
 - oral cavity infections in, due to *Candida*, 1554
 - parvovirus B19 infections in, e122, 1361
 - pathogenesis, 1738, 1756
 - in pediatric patients (see Pediatric patients, human immunodeficiency virus infection in)
 - penicilliosis in, e78
 - Penicillium marneffei* infections in, 955
 - Pneumocystis carinii* infections in, 955
 - disseminated, 254, 300
 - thoracic, 498
 - tuberculosis with, 289
 - pneumonia in, due to measles virus, e57
 - in pregnancy, iron status and, 1496
 - prevention
 - hypercholesterolemia in, 1635
 - postexposure prophylaxis, 1494
 - probiotics in, 1567, 1577
 - vaginal microbicides in, 476
 - primary
 - clinical features, 1756
 - natural history, 1756
 - rhabdomyolysis in, 502
 - treatment, 1738
 - cerebrospinal fluid RNA measurement, 1095
 - progression, 1756
 - after influenza, 1366
 - quality of life in, measurement, e524
 - resistance in, detection, 774

- retinitis in, due to cytomegalovirus, 815
 - treatment, Current News, May 1
- Rhodococcus equi* infections in, e39, 929, 970
- risk factors, in Thailand, 955
- Salmonella* infections in, 263
- Scedosporium prolificans* infections in, e158
- sexually transmitted diseases in, 611
 - screening for, 808
- Staphylococcus aureus* infections in, methicillin-resistant, in injection drug users, 581
- Streptococcus pneumoniae* infections in, 794
 - in pediatric patients, 1155
- syphilis in, 611, 667
- T lymphocytes in (see T lymphocytes, in HIV infection)
- transmission
 - polio vaccine hypothesis, 1068
 - prevention, 1494
 - probiotics in, 1567, 1577
 - vaginal microbicides in, 476
 - between primate species, 1068
 - by travelers, 1732
- treatment (see also Highly active antiretroviral therapy; specific drugs)
 - complications, 124
 - drug resistance in, 774
 - with hepatitis C, 963
 - immune-based, 1738, 1756
 - immune restoration in [letter], 325
 - measles vaccination response, 1090
 - neutropenia due to, 469
 - nutritional problems in, 1769
 - ototoxicity in, 1623
 - paronychia in, 140
 - parvovirus B19 infection resolution in, e122
 - in pediatric patients, 464
 - primary, 1095
 - spinal epidural lipomatosis due to, e90
 - virologic rebound in, 1231
- trichomoniasis in, 611
 - screening for, 808
- tuberculosis in
 - chemokine receptor expression in, 650
 - multidrug-resistant, 159
 - Pneumocystis carinii* infections with, 289
 - recurrence, 515
 - in Thailand, 955
 - treatment, 321 [letters and reply], 623
- Ureaplasma urealyticum* infections in, 611
- urethritis in, 611
- vaccination, in neonates, 801
- virus load in
 - vs. iron status, 1496
 - treatment effects on, 1738
- wasting in, antibiotic prophylaxis in, 116
- weight management in, 1769
- Human monocytic ehrlichiosis, review, 897
- Human papillomavirus infections
 - in HIV infection, 611
 - pathology, 1589
 - respiratory, treatment with cidofovir, e62
- Human parvovirus B19 infections (see Parvovirus B19 infections)
- Human T cell lymphotropic/leukemia virus type 1 infections, myelopathy associated with, inclusion body myositis in, 510
- Humoral immune response, T lymphocytes in, type 1/type 2 immunity, 76
- Hyalomma* species, review, 897
- Hydatidosis, of thigh muscle, treatment, e65
- Hydrogen peroxide, produced by viridans streptococci, in methicillin-resistant *Staphylococcus aureus* colonization, in newborns, 1408
- Hydroxyurea, for HIV infection, 1738
- Hypercholesterolemia
 - in HIV infection, 130
 - due to HIV prophylaxis, 1635
- Hypersensitivity
 - delayed, pathogenesis, e17
 - to fluoroquinolones, S72
- Hypertension, in HIV infection, 130
- Hypertriglyceridemia, in HIV infection, 130
- Hypogammaglobulinemia, in Good's syndrome, adult-onset [letter], 323
- Hypopituitarism, immunodeficiency in, 153
- Hypotension, in *Neisseria meningitidis* infections, in pediatric patients, 1004
- IDSA (see Infectious Diseases Society of America)
- IFN- α (see Interferon- α)
- IFN- γ (see Interferon- γ)
- IL(s) (see Interleukin[s])
- Imipenem
 - for febrile neutropenia, 381
 - for intravascular catheter-related infections, 1249
 - resistance to, 1162
 - Pseudomonas aeruginosa*, S146
 - Streptococcus pneumoniae*, 1463
- Imiquimod, for human papillomavirus infections, 611
- Immune complexes, pneumolysin antibody detection in, 534
- Immune globulin, for Kawasaki-like syndromes, in HIV infection, 1628
- Immune response
 - HIV, 1738, 1756
 - pathology of, 1589
 - T lymphocytes in, type 1/type 2 immunity, 76
- Immune system, reconstitution, mycobacterial infections and [letter and reply], 845, 846
- Immunization (see Vaccines and vaccination)
- Immunoblot assay, as independent test [letter], 1114
- Immunodeficiency (see also Human immunodeficiency virus infection; Neutropenia; Transplantation)
 - Aspergillus* infections in, mortality in, 358
 - Bacillus cereus* infections in, in pediatric patients, 1456
 - Enterococcus* bacteremia in, 1540
 - enterovirus infections in, treatment with pleconaril, e13
 - in panhypopituitarism, 153
 - Salmonella* infections in, 263
 - Scedosporium prolificans* infections in, e158
- Immunofluorescence test
 - for parainfluenza virus, 413
 - for rickettsiae, 897
- Immunoglobulin(s)
 - in paragonimiasis, e171
 - therapeutic (see Immune globulin)
- Immunoglobulin G, pneumolysin, assays for, 534
- Immunohistochemistry, for infection diagnosis, 1589
- Immunosuppressive therapy
 - for HIV infection, 1738
- Immunotherapy
 - for HIV infection, 1738
 - Salmonella* infections related to, 263
 - T lymphocyte type 1/type 2 immunity and, 76
- Inclusion body myositis, in human T cell leukemia virus type 1 virus-associated myelopathy, 510
- Indinavir, for HIV infection, paronychia in, 140
- Infarction, brain, in *Mycoplasma pneumoniae* infections, e31
- Infection control
 - artificial nails and, 352, 367
 - Creutzfeldt-Jacob disease, 1348

- fellowship training on, adequacy of, 255
- mask aversion and [letter], 991
- prion diseases, 1726
- in simulated bioterrorist attack, 436
- tickborne diseases, 897
- for vancomycin resistance prevention, 108
- vancomycin-resistant *Enterococcus*, 826
- zoonotic diseases, 446
- Infectious Diseases Society of America
 - guidelines
 - development, 851
 - infectious diarrhea, 331
 - intravascular catheter-related infections, 1249
 - lecture at 2000 annual meeting, 675
 - policy statement, on consolidation of clinical microbiology laboratories, 604, 605
 - training program, 755
- Influenza
 - epidemiology, Current News, May 1
 - in HIV infection
 - outbreaks, 1784
 - progression after, 1366
 - outbreaks
 - in HIV infection, 1784
 - from imported virus, 1639
 - pandemic, potential for, 675
 - vaccination, in HIV infection, 1784
- Information resources, Internet (see Internet resources)
- In situ hybridization test, for infection diagnosis, 1589
- Insulin resistance, in HIV infection, 130
- Intensive care unit
 - diabetic ketoacidosis in, infection as trigger, 30
 - gram-negative infections in, in neonates, 220
 - prophylactic antifungal therapy in, 1191
- Interferon- α , for HIV infection, 1738
- Interferon- γ
 - for brain abscess, due to *Aspergillus*, e137
 - for *Mycobacterium avium* complex infections, in HIV infection, e81
 - T lymphocyte type 1/type 2 immunity and, 76
- Interleukin(s)
 - for HIV infection, 1738, 1756
 - T lymphocyte type 1/type 2 immunity and, 76
- Interleukin-2, for HIV infection, 766
- Interleukin-8, in gram-negative bacteremia prediction, in neutropenia, 832
- International-Infectious Disease Society for Obstetric and Gynecology-USA, on Centers for Disease Control and Prevention pelvic inflammatory disease guidelines, 103
- Internet resources
 - emerging infections, 270
 - travel medicine, 757
 - tuberculosis, 1580
- Intracranial hypertension, in enterovirus 71 infections, 236
- Iron status, as HIV severity marker, 1496
- Isosporiasis, practice guidelines, 331
- Itraconazole
 - for alternariosis, in diabetes mellitus, 1178
 - for aspergillosis, in bone marrow transplantation, e94
 - for basidiobolomycosis, 1448
 - for brain abscess, due to *Aspergillus*, e137
 - for histoplasmosis, in HIV infection, 483
 - for lymphadenitis, due to *Scedosporium apiospermum*, e59
- Ixodidae (hard ticks), review, 897
- Janeway lesions, due to *Brucella* endocarditis, 63, 149
- Jaundice, in malaria, 1133
- JC virus infections
 - in bone marrow transplantation, 1325
 - treatment, failure, 150
- Joint infections
 - prosthetic, hip, treatment, 419
 - due to *Staphylococcus aureus*, 647
- Juvenile rheumatoid arthritis, *Bartonella* infections in, e22
- Kala-azar (see Leishmaniasis, visceral)
- Kanamycin, for refractory tuberculosis, 44
- Kaposi's sarcoma
 - after kidney transplantation, 1502
 - arcoidosis with, virus detection in, 1100
- Kawasaki disease, in HIV infection, 1628
- Kenyon stain, for infection diagnosis, 1589
- Keratinocytes, *Staphylococcus aureus* persistence in, 1643
- Ketoacidosis, diabetic, infection as trigger, 30
- Ketoconazole
 - for intravascular catheter-related infections, 1249
 - prophylactic, in neutropenia, bacteremia breakthrough and, 1532, 1538
 - resistance to, *Candida*, 1554
- Kidney
 - dysfunction and failure
 - in amphotericin B toxicity, 686, 990 [letter]
 - in babesiosis, 1117
 - in candidiasis, in neonates, 1018
 - in fluoroquinolone toxicity, S72
 - in HIV infection, 1487
 - Highly active antiretroviral therapy effects on, in pediatric patients, 464
 - in malaria, 1133
 - infections
 - due to *Candida*, 1602
 - due to parvovirus B19, 167
 - transplantation
 - cytomegalovirus infections in, prevention, 742
 - genitourinary tuberculosis after, 662
 - human herpesvirus 6 and 7 infections in, 1357
 - human herpesvirus 8 detection, Kaposi's sarcoma development, 1502
- Klebsiella pneumoniae* infections, resistance in
 - extended-spectrum β -lactamase-producing, 1162
 - global, S94, S156
 - trimethoprim-sulfamethoxazole, 1608
- Koprowski hypothesis, for HIV transmission in poliovirus vaccine, 1068
- Kuru, clinical implications, 1726
- Laboratories, clinical microbiology, consolidation, Infectious Diseases Society of America policy statement on, 604, 605
- β -Lactamases
 - extended-spectrum, 1162
 - global resistance studies, S94, S156
 - new, antibiotic therapy selection and, 1085
- Lactobacillus*, vaginal, e69
 - variation during menstrual cycle [letter], 325
- Lactobacillus* infections, T lymphocyte type 1/type 2 immunity in, 76
- Lactobacillus rhamnosus*, as probiotic, 1567, 1577
- Laminectomy, *Candida* infections after, 352
- Lamivudine
 - for HIV infection
 - with hepatitis C, 963
 - prophylactic, 1494
 - resistance to, monitoring, 774
- Larynx, papillomatosis in, due to human papillomavirus, treatment with
 - cidofovir, e62
- Lassa fever, nosocomial, prevention, 446
- Leclercia adacarboxylata* infections, in pediatric patients [letter], 1659

- Legionella* infections
 pathology, 1589
 pneumonia, treatment failure, 1562
- Leishmaniasis
 cutaneous, *braziliensis* vs. *guyanensis*, 1304
 T lymphocyte type 1/type 2 immunity in, 76
 visceral
 in HIV infection, highly active antiretroviral therapy effects on, 633
 without endemic area exposure, 302
- Leprosy
 in immunorestitution disease [letter and reply], 845, 846
 T lymphocyte type 1/type 2 immunity in, 76
 in United States immigrants, 930
- Leukemia
Candida lusitanae infections in, 186
 cytomegalovirus infections in, 539
Leclercia adecarboxylata infections in [letter], 1659
Scedosporium prolificans infections in, e158
- Leukocyte counts, during human granulocytic ehrlichiosis, 862
- Leukocyte infusion, for adenovirus infections, in stem cell transplantation, 1290
- Leukoencephalopathy, progressive multifocal, treatment, failure, 150
- Leukopenia, in ehrlichiosis, 862
- Leukotrienes, T lymphocyte type 1/type 2 immunity and, 76
- Levofloxacin
 for meningitis, tuberculous, 643
 pharmacodynamics, S39
 staphylococcal infections, S33
 resistance to, 1162
Pseudomonas aeruginosa, S146
Streptococcus pneumoniae, 701
 for respiratory infections, S39
 toxicity, S72
- Lidocaine, for herpes zoster, 1481
- Linezolid
 for endocarditis, due to *Enterococcus*, 1373
 for intravascular catheter-related infections, 1249
 for pneumonia, nosocomial, 402
- Lipodystrophy, in HIV infection, 130
- Lipomatosis, spinal, due to corticosteroids, e90
- Listeriosis
 foodborne, treatment [letter and reply], 1518, 1519
 resistance in, trimethoprim-sulfamethoxazole, 1608
 T lymphocyte type 1/type 2 immunity in, 76
- Liver
 abscess
 due to *Brucella*, 1024
 due to *Fusobacterium nucleatum* [letter], 326
 disorders
 due to amphotericin B lipid formulations, e87
 due to *Babesia*, 1117
 due to *Candida*, in neonates, 1018
 due to *Fasciola hepatica*, 727, 820, 1658 [letter]
 due to fluoroquinolones, S72
 in HIV infection, 1487
 mortality in, 492, 1207
 transplantation
 cytomegalovirus infections in, prevention, 742
 hepatitis A vaccination in [letter], 1656
 human herpesvirus 6 and 7 infections in, 1357
- Loracarbef, resistance to, *Streptococcus pneumoniae*, S81
- Lumbar puncture, mask use in, aversion to [letter], 991
- Lung (see also Pneumonia; Tuberculosis)
 aspiration from, for pneumonia diagnosis, in pediatric patients, 715
 cancer, *Legionella* infections in, treatment failure, 1562
 fibrosis, in ankylosing spondylitis, 1062, 1103
 transplantation, cytomegalovirus infections in, 742
- Lyme disease
 as nonspecific fever cause, 1434
 review, 897
- Lymphadenitis
 due to *Burkholderia pseudomallei*, 653
 due to *Scedosporium apiospermum*, e59
- Lymphangitis
 due to *Leishmania*, *braziliensis* vs. *guyanensis*, 1304
 sporotrichoid, due to *Streptococcus* group A, e176
- Lymphocytopenia
 in ehrlichiosis, 862
 liver abscess in, due to *Fusobacterium nucleatum* [letter], 326
- Lymphoma
Candida lusitanae infections in, 186
 in HIV infection, acyclovir and [letter], 989
- Mad cow disease
 clinical implications, 1726
 prevention, disinfection and sterilization for, 1348
- Magnetic resonance imaging, of spinal cord gnathostomiasis, e154
- Malaria
 epidemiology, Georgia, e124
 due to *Plasmodium falciparum*
 blackwater fever in, 1133
 treatment, in pediatric patients, 838
- Malassezia furfur* infections, catheter-related, guidelines, 1249
- Marburg virus infections, nosocomial, prevention, 446
- Masks, in lumbar puncture, aversion to [letter], 991
- Measles
 giant cell pneumonia in, in HIV infection, e57
 subclinical, subacute sclerosing panencephalitis in, 173
 vaccination, in HIV infection, highly active antiretroviral therapy effects on, 1090
- Mebendazole, for trichinosis, failure, 638
- Mediastinitis, due to *Staphylococcus aureus*, methicillin resistance and, 877
- Medical Letter, The, for travel medicine information, 757
- Medical Outcomes Study, in HIV infection quality of life measurement, e47
- Medicare, pneumonia overcharges, Current News, May 15
- Mediterranean spotted fever, review, 897
- Medulla, spinal cord, gnathostomiasis, e154
- Mefloquine, blackwater fever due to, 1133
- Megestrol acetate, for wasting, in HIV infection, 116
- Melioidosis
 in cystic fibrosis, e15
 epidemiology, Laos, 653
- Meningitis
 aseptic
 due to enterovirus 71, 236
 after neurological surgery, vs. bacterial meningitis, 179
 due to *Bacillus cereus*, in immunodeficiency, in pediatric patients, 1456
 due to *Cryptococcus neoformans*
 in cancer, e145
 in HIV infection, 836
 epidemiology, in pediatric patients, in Africa, 64
 fever interval in, in pediatric patients, 566
 Mollaret's, pathology, 1589
 due to *Mycoplasma pneumoniae*, e31
 due to *Neisseria meningitidis*, epidemiology, 1004
 due to *Rickettsia prowazekii*, 979
 due to *Streptococcus pneumoniae*, serogroups, in pediatric patients, 1155
 tuberculous, treatment, 643

- Meningococcal infections
 epidemiology, in pediatric patients
 in Africa, 64
 in Massachusetts, 1004
 meningitis, fever interval in, in pediatric patients, 566
 risk factors, invasive, in school workers, 1795
 vaccination
 intramuscular vs. subcutaneous, 170
 safety data, 1273
- Meningoencephalitis, in *Mycoplasma pneumoniae* infections, e31
- Menstrual cycle, vaginal microflora variation during [letter], 325
- Meropenem, resistance to
 Acinetobacter, S104
 Pseudomonas aeruginosa, S146
- Metallo- β -lactamases, antibiotic therapy selection and, 1085
- Metamizol, for malaria, in pediatric patients, 838
- Methicillin, resistance to
 coagulase-negative *Staphylococcus*, S114
 Staphylococcus aureus (see *Staphylococcus aureus* infections, methicillin-resistant)
- Methylprednisolone
 for herpes zoster, 1481
 in T lymphocyte type 1/type 2 immunity, 76
- Metronidazole
 for diarrhea, 331
 for histoplasmosis, in HIV infection, 483
 resistance to, *Giardia lamblia*, 1792
- Microbicides, vaginal, safety, 476
- Microbiology
 clinical laboratories for, consolidation, Infectious Diseases Society of America policy statement on, 604, 605
 fellowship training on, adequacy of, 255
- β_2 -Microglobulin, measurement, in primary HIV infection, treatment effects, 1095
- Microsporidium* infections, practice guidelines, 331
- Minocycline, for leprosy, 930
- Mollaret's meningitis, pathology, 1589
- Molluscum contagiosum* infections, pathology, 1589
- Monkeypox, nosocomial, prevention, 446
- Monobactams, resistance to, new β -lactamases and, 1085
- Moraxella catarrhalis* infections
 pneumonia, in Finland, 1141
 resistance in
 global, S81
 trimethoprim-sulfamethoxazole, 1608
 treatment, moxifloxacin, S51
- Mortality
 in adenovirus infections, 1423
 in bone marrow transplantation, 871
 in *Aspergillus* infections, 358
 in babesiosis, 1117
 in bee sting infections, e36
 in *Candida lusitanae* infections, 186
 in candidiasis, in cancer, 1713
 in cytomegalovirus infections, in leukemia, 539
 in diarrhea, 331
 in endocarditis, fungal, 50
 in *Enterococcus bacteremia*, 587
 in fungal infections, in bone marrow transplantation, 1319
 in HIV infection, with hepatitis C, 492, 1207
 in human immunodeficiency virus infection, 492, 1207, 1487
 in infectious complications
 bone marrow or stem cell transplantation, 391
 hip arthroplasty, 419
 in kidney failure in amphotericin B therapy, 686
 in measles, in HIV infection, e57
 in meningitis
 in African children, 64
 fever interval and, 566
 in meningococemia, 1338
 in *Neisseria gonorrhoeae* septic shock, e92
 in *Neisseria meningitidis* infections, in pediatric patients, 1004
 in panhypopituitarism, due to infections, 153
 in penicilliosis, in HIV infection, e78
 in *Rhodococcus equi* infections, e39
 in *Staphylococcus aureus* mediastinitis, methicillin resistance and, 877
 in toxoplasmosis, in stem cell transplantation, e1
 in tuberculosis, drug-resistant, 373
- Mosquitoes, in disease transmission
 dengue hemorrhagic fever, 204, 243
 West Nile virus, 277
- Mouth (see Oral cavity)
- Moxifloxacin
 activity, S16
 clinical evaluation, S51
 respiratory pathogens, S64
 Streptococcus pneumoniae, S22
 Streptococcus pyogenes, S30
 interactions with, S47
 mechanisms of action, S9
 for penicillin-resistant *Streptococcus pneumoniae* infections, S22
 pharmacodynamics, S22, S33, S39, S47, S51
 resistance to, S1, S16, S51
 for respiratory tract infections, S64
 safety profile [letter], 1112
 side effects, S51
 toxicity, S72, 1112 [letter]
- Mucormycosis
 pathology, 1589
 treatment with granulocyte-macrophage colony-stimulating factor, e166
- Multiple organ failure syndrome
 in HIV infection, 1487
 human herpesvirus type 6 reactivation in, 197
- Muscle disorders (see also Myositis)
 in babesiosis, 1117
 in human T cell leukemia virus type 1 virus-associated myelopathy, 510
 hydatidosis, treatment, e65
 necrosis, due to *Edwardsiella tarda*, 1430
 due to quinupristin-dalfopristin, e83
 rhabdomyolysis, in HIV infection, 502
- Myalgia
 in babesiosis, 1117
 due to quinupristin-dalfopristin, e83
- Mycobacterium abscessus* infections
 in cystic fibrosis, 1648
 in HIV infection, 432
 osteomyelitis, 1506
- Mycobacterium avium* complex infections
 in cystic fibrosis, 1298
 in HIV infection
 prophylaxis, 116, 1615
 treatment, e81
 in immunorestitution disease [letter and reply], 845, 846
 osteomyelitis, 1506
 respiratory, treatment, 1547
- Mycobacterium bovis* infections
 osteomyelitis, 1506
 strain B, nosocomial outbreak, 159
- Mycobacterium chelonae* infections, in cystic fibrosis, 1298
- Mycobacterium* infections

- catheter-related, guidelines, 1249
nontuberculous, in cystic fibrosis, 1298
pathology, 1589
T lymphocyte type 1/type 2 immunity in, 76
- Mycobacterium leprae* infections (see Leprosy)
Mycobacterium tuberculosis (see Tuberculosis)
Mycophenolate mofetil, for HIV infection, 1738
- Mycoplasma genitalium* infections
in HIV infection, 611
urethritis, 995
- Mycoplasma pneumoniae* infections
encephalitis, in pediatric patients, 1674
neurologic disorders in, e31
pneumonia
in Finland, 1141
in pediatric patients, 1281
Still's disease in, e105
- Myelitis
due to *Cryptococcus neoformans*, 1235
transverse, in enterovirus 71 infections, 236
- Myelopathy, due to human T cell leukemia virus type 1 virus, inclusion body myositis in, 510
- Myelosuppression, in HIV infection, natural history, 469
- Myocarditis, due to *Coxiella burnetii*, 1440
- Myonecrosis, due to *Edwardsiella tarda*, 1430
- Myositis
due to *Cryptococcus neoformans*, in hepatitis C, 1104
inclusion body, in human T cell leukemia virus type 1 virus-associated myelopathy, 510
- Nafcillin, for intravascular catheter-related infections, 1249
- Nail(s)
acrodermatitis continua of Hallopeau, 431, 505
artificial, in health care workers
Candida infections related to, 352
hand cleansing methods and, 367
disorders, due to indinavir, 140
- Nalidixic acid, for diarrhea, 331
- Nandrolone, for wasting, in HIV infection, 116
- Naproxen, for malaria, in pediatric patients, 838
- Necrosis
avascular, bone, in HIV infection, 1221
muscle, due to *Edwardsiella tarda*, 1430
in spider bite, 595, 636
- Necrotizing fasciitis, due to β -hemolytic streptococci, laboratory tests for, e9
- Neisseria gonorrhoeae* infections
diagnosis, 655
in HIV infection, 611
pelvic inflammatory disease, Centers for Disease Control and Prevention guidelines, 103
resistance in
ciprofloxacin, 1313
fluoroquinolones, 884
shock in, e92
treatment, 1313
failure, 884
- Neisseria* infections, resistance in, trimethoprim-sulfamethoxazole, 1608
- Neisseria meningitidis* infections
bacteremia, protein C replacement in, 1338
epidemiology, in pediatric patients, in Massachusetts, 1004
meningitis, fever interval in, in pediatric patients, 566
resistance in, sulfonamides, 1608
vaccines, safety data, 1273
- Nelfinavir, for HIV infection, prophylactic, 1494
- Neonatal infections
due to *Candida*, 1579, 1637
systemic involvement, 1018
due to gram-negative organisms, in intensive care unit, 220
due to HIV, vaccination for, 801
sepsis
due to *Campylobacter jejuni*, e97
due to gram-negative organisms, Current News, May 15
due to streptococci group B, prophylaxis, Current News, May 15
- Neonates, methicillin-resistant *Staphylococcus aureus* colonization in, viridans streptococci effects on, 1399, 1408
- Nephropathy (see Kidney, dysfunction and failure)
- Neuralgia, postherpetic
in elderly persons, 1481
after stem cell transplantation, 1414
- Neurological disorders (see also Encephalitis; Meningitis)
due to enterovirus 71, in pediatric patients, 236
due to fluoroquinolones, 572
due to *Gnathostoma spinigerum*, e154
human T cell leukemia virus type 1 virus-associated myelopathy, 510
due to *Mycobacterium leprae*, 930
due to *Mycoplasma pneumoniae*, e31
due to prions, 1726
due to tickborne pathogens, 897
tick paralysis, 897
due to *Toxoplasma gondii*, in stem cell transplantation, e1
due to *Treponema pallidum*, vs. herpes simplex virus encephalitis, 1108
- Neurological surgery, chemical meningitis after, vs. bacterial meningitis, 179
- Neurosyphilis
vs. herpes simplex virus encephalitis, 1108
in HIV infection, 611
uveitis and, 1661
- Neutropenia
Aspergillus infections in, mortality in, 358
Bacillus cereus infections in, in pediatric patients, 1456
bacteremia in, due to *Abiotrophia*, e140
in cancer
bacteremia breakthrough, antifungal prophylaxis and, 1532, 1538
breast, 546
candidemia in, outcome, 1713
Cryptococcus neoformans infections in, e145
gram-negative bacteremia prediction in, 832
treatment, in children, 36
Candida lusitanae infections in, 186
Clostridium tertium bacteremia in, 975
empirical antifungal therapy for [letter and reply], 320, 518
in HIV infection
natural history, 469
treatment, 766
infection detection in, procalcitonin for, 1718
treatment, 381
- Nevirapine
for HIV infection
complications, 124
ototoxicity, 1623
resistance to, monitoring, 774
- Nippostrongylus* infections, T lymphocyte type 1/type 2 immunity in, 76
- Nitazoxanide, for giardiasis, in HIV infection, 1792
- Nitrofurantoin, resistance to, *Enterococcus*, S133
- Nocardia asteroides* infections, endocarditis, 660
- Nocardia* infections, pathology, 1589
- Norfloxacin
for brain abscess, due to *Streptococcus intermedius*, e131
for diarrhea, 331
resistance to, S1

- Nortriptyline, for herpes zoster, 1481
- Nosocomial infections (*see also* Catheter-related infections)
- due to *Acinetobacter*, resistance in, S104
 - due to adenovirus, type 7d2, in pediatric patients, 694
 - due to *Candida*
 - costs [letter], 1100
 - review, 1602
 - spinal, 352
 - diarrhea, practice guidelines, 331
 - due to gram-negative organisms, in neonatal intensive care unit, 220
 - meningitis, after neurological surgery, 179
 - due to *Mycobacterium bovis* strain B, 159
 - pneumonia, treatment, 402
 - due to prions, prevention, 1348
 - due to *Staphylococcus aureus*, colonization duration, 1393
 - due to *Stenotrophomonas maltophilia*, resistance in, S104
 - due to *Streptococcus pneumoniae*, levofloxacin-resistant, 701
 - due to zoonotic organisms, review, 446
- Nursing homes, methicillin-resistant *Staphylococcus aureus* carriage in, 1393
- Nutrition, in HIV infection, with highly active antiretroviral therapy, 1769
- Nystatin, prophylactic, in intensive care unit, 1191
- Obesity, due to HIV therapy, 1769
- Occupational disorders, meningococcal infections, in school workers, 1795
- Ochrobacterium anthropi* infections, catheter-related, guidelines, 1249
- Office management, fellowship training on, adequacy of, 255
- Ofloxacin
 - for diarrhea, 331
 - for gonorrhea, in HIV infection, 611
 - for leprosy, 930
 - for pelvic inflammatory disease, 103
 - resistance to, S1, 1162
- Opiates, for herpes zoster, 1481
- Opso-mycloclonus syndrome, in enterovirus 71 infections, 236
- Optic neuritis, due to *Treponema pallidum*, 1661
- Oral cavity
 - infections
 - due to *Candida*, in HIV infection, 1554
 - due to *Gongylonema*, 1378
 - due to human papillomavirus, in HIV infection, 611
 - methicillin-resistant *Staphylococcus aureus* colonization, viridans streptococci inhibition, in neonates, 1399, 1408
- Oral rehydration therapy, for diarrhea, 331
- Ornithodoros* species, review, 897
- Osler's nodes, due to *Brucella* endocarditis, 63, 149
- Osteitis, due to *Treponema pallidum*, in HIV infection, 667
- Osteomyelitis
 - due to *Salmonella*, 263
 - spinal
 - due to *Candida*, 352, 527
 - due to nontuberculous mycobacteria, 1506
 - in pediatric patients, 9
 - due to *Staphylococcus aureus*, methicillin-resistant, in injection drug users, 581
- Ototoxicity, nucleoside analog reverse transcriptase inhibitors, 1623
- Outbreaks
 - adenovirus infections, type 7d2, in pediatric patients, 694
 - cyclosporiasis, Missouri, 1010
 - diarrhea, 331
 - gram-negative infections, in neonatal intensive care unit, 220
 - influenza
 - in HIV infection, 1784
 - from imported virus, 1639
 - Staphylococcus aureus* infections, methicillin-resistant, 581
 - tuberculosis, multidrug-resistant, 159
 - West Nile viral encephalitis, New York City, 277
- Outcome
 - candidemia in cancer, 1713
 - of pneumonia management, practice guidelines effects on, 728
- Pain, in herpes zoster, 1481
- Pancreas, transplantation, human herpesvirus 6 and 7 infections in, 1357
- Pancreatitis, in HIV infection, 1487
- Panhypopituitarism, immunodeficiency in, 153
- Pantoea agglomerans* infections
 - bacteremia, venous port-related, 1776
 - resistance in, fluoroquinolones, 162
- Papanicolaou stain, for infection diagnosis, 1589
- pap* genotype, *Escherichia coli*, in urinary tract infections, 1523
- Papillomatosis, respiratory, treatment with cidofovir, e62
- Paragonimiasis, clinical features, e171
- Parainfluenza virus infections, after stem cell transplantation, 413
- Paralysis, tick, 897
- Paromomycin, for cryptosporidiosis [letter and reply], 1516, 1517
- Paraplegia, due to *Gnathostoma spinigerum*, e154
- Parasitic infections, pathology, 1589
- Paresthesia, meningococcal vaccines, 1273
- Paronychia, due to indinavir, 140
- Parvovirus B19 infections
 - in HIV infection, e122, 1361
 - renal involvement in, 167
 - thrombotic thrombocytopenic purpura-like syndrome in, 311
- Pasteurella gallinarum*, *Haemophilus aphrophilus* misidentified as [letter and reply], 987, 989
- Pathology, in infection diagnosis, 1589
- PCR (*see* Polymerase chain reaction)
- Pediatric patients (*see also* Neonatal infections)
 - adenovirus infection outbreak, type 7d2, 694
 - Bacillus cereus* infections in, in immunodeficiency, 1456
 - candidiasis in, 1579, 1637
 - catheter-related infections in, guidelines, 1249
 - Chlamydia pneumoniae* infections in, 1281
 - Chromobacterium violaceum* sepsis in, e107
 - dengue hemorrhagic fever in
 - microvascular leakage in, noninvasive measurement, 243
 - treatment, 204
 - diarrhea in, practice guidelines, 331
 - enterovirus infections in, treatment with pleconaril, e13
 - enterovirus 71 infections in, neurological manifestations, 236
 - febrile neutropenia in, in cancer, treatment, 36
 - Helicobacter pylori* infections in, breast-feeding practices and, 1387
 - HIV infection, treatment, 464
 - HIV infections in
 - Streptococcus pneumoniae* infections in, 1155
 - vaccination for, 801, 1090
 - Leclercia adacarboxylata* infections in [letter], 1659
 - malaria in, treatment, 838
 - meningitis in, fever interval in, 566
 - Mycoplasma pneumoniae* infections in
 - encephalitis, 1674
 - pneumonia, 1281
 - Neisseria meningitidis* infections in, 1004
 - Pneumocystis carinii* infections in, detection, 855
 - pneumonia in, 715, 1281
 - rotavirus infections in, severity, vs. strain, 1126
 - septic bursitis in, e102
 - spinal epidural abscess in, 9
 - Streptococcus pneumoniae* colonization in, Indonesia, 1039
 - Streptococcus pneumoniae* infections in

- invasive, serogroups, 1155
- urinary assay for, 824
- tuberculosis in, diagnosis, 17
- visceral leishmaniasis in, without endemic area exposure, 302
- Pelvic inflammatory disease, treatment, Centers for Disease Control and Prevention guidelines, 103
- Penicillin(s)
 - allergy to, skin tests for, 317, 1685
 - for intravascular catheter-related infections, 1249
 - resistance to
 - Moraxella catarrhalis*, S81
 - new β -lactamases and, 1085
 - Streptococcus pneumoniae*, S22, S81, 972, 1044, 1463
 - for syphilis, 1661
 - in HIV infection, 611
 - for uveitis, due to *Treponema pallidum*, 1661
- Penicillin G, for Whipple's disease, 457
- Penicilliosis, in HIV infection, e78, 955
- Pentamidine, prophylactic, for *Mycobacterium avium* complex infections, in HIV infection, 1615
- Pentoxifylline, for chronic venous disease, 949
- Periodic acid-Schiff stain, for infection diagnosis, 1589
- Peripheral neuropathy, in *Mycoplasma pneumoniae* infections, e31
- Pertussis
 - in adults and adolescents, 1691, 1698
 - epidemiology, in elderly persons [letter], 847
- P fimbriae, *Escherichia coli*, in urinary tract infections, 1523
- Phagocytosis, T lymphocyte type 1/type 2 immunity and, 76
- Pharmacodynamics (see also specific drug)
 - principles, practical use, S39
- Pharmacokinetics, principles, practical use, S39
- Pharyngitis
 - due to *Neisseria gonorrhoeae*, in HIV infection, 611
 - due to streptococci group A, treatment, S30, 1798
- Pharynx, papillomatosis in, treatment with cidofovir, e62
- Phenotyping, in drug resistance detection, in HIV infection, 774
- Phototoxicity, fluoroquinolones, S72
- Piperacillin, resistance to
 - Acinetobacter*, S104
 - Pseudomonas aeruginosa*, S146
- Piperacillin-tazobactam, resistance to
 - Acinetobacter*, S104
 - Pseudomonas aeruginosa*, S146
 - Stenotrophomonas maltophilia*, S104
- Pituitary insufficiency, immunodeficiency in, 153
- Plague
 - nosocomial, prevention, 446
 - in simulated bioterrorist attack, drill for, 436
- Plasmid analysis, for microorganisms in global resistance surveillance program, S156
- Plasmodium falciparum* malaria
 - blackwater fever in, 1133
 - treatment, in pediatric patients, 838
- Platelet counts, in ehrlichiosis, 862
- Pleconaril, for enterovirus infections, 228
 - in immunodeficiency, e13
- Plesiomonas* infections, diarrhea, practice guidelines, 331
- Plethysmography, in microvascular leakage measurement, in dengue hemorrhagic fever, 243
- Pleura, *Pneumocystis carinii* infections, in HIV infection, 498
- Pleurisy, due to *Paragonimus westermani*, clinical features, e171
- Pneumococcal infections (see *Streptococcus pneumoniae* infections)
- Pneumocystis carinii* infections
 - detection, in pediatric patients, 855
 - in HIV infection, 955
 - disseminated, 254, 300
 - pneumonia, 116, 289, 955
 - thoracic, 498
 - tuberculosis with, 289
- pathology, 1589
- pneumonia, in HIV infection, 116, 289, 955
- Pneumolysin, antibodies to, in *Streptococcus pneumoniae* infection diagnosis, 534
- Pneumonia
 - due to adenovirus
 - in bone marrow transplantation, 871
 - in Korean children, 1423
 - due to *Blastomyces dermatitidis*, public health response to, in Colorado, e151
 - after bone marrow or stem cell transplantation, 546
 - due to *Chlamydia pneumoniae*, in pediatric patients, 1281
 - due to *Coccidioides immitis*, risk factors for, 708
 - due to cytomegalovirus, in leukemia, 539
 - epidemiology, Finland, 1141
 - etiology, in Finland, 1141
 - in HIV infection
 - Mycobacterium avium* complex prophylaxis and, 1615
 - due to *Pneumocystis carinii*, 116, 289, 955
 - due to *Legionella*, treatment failure, 1562
 - lung tap for, in pediatric patients, 715
 - due to measles virus, in HIV infection, e57
 - Medicare overcharges for, Current News, May 15
 - due to *Mycoplasma pneumoniae*, in pediatric patients, 1281
 - in panhypopituitarism, 153
 - due to parainfluenza virus, after stem cell transplantation, treatment, 413
 - due to *Pneumocystis carinii*, in HIV infection, 955
 - antibiotic prophylaxis for, 116
 - tuberculosis with, 289
 - practice guidelines for, cost-effectiveness, 728
 - due to *Staphylococcus*, resistance in, S114
 - due to *Staphylococcus aureus*, methicillin-resistant, in injection drug users, 581
 - due to *Streptococcus pneumoniae*
 - in HIV infection, 794
 - pneumolysin antibody detection in, 534
 - round mass in, 1188, 1233
 - treatment, S22
 - treatment
 - fluoroquinolones, S39
 - moxifloxacin, S22, S51, S64
- Pneumothorax, in lung tap, 715
- Podofilox, for human papillomavirus infections, 611
- Podophyllin, for human papillomavirus infections, 611
- Polarization, of T lymphocytes, 76
- Poliomyelitis
 - eradication, Current News, May 1
 - vaccination, HIV transmission hypothesis, 1068
- Polymerase chain reaction
 - for *Cyclospora*, 1010
 - for cytomegalovirus, 783
 - for *Escherichia coli* pap genotype, 1523
 - for human herpesvirus type 6, 197
 - for HIV
 - non-B subtype, 1227
 - in poliovirus vaccine, 1068
 - for infection diagnosis, 1589
 - for microorganisms in global resistance surveillance program, S156
 - for *Mycobacterium leprae*, 930
 - for *Mycobacterium tuberculosis*, in pediatric patients, 17
 - for *Mycoplasma pneumoniae*, e31, 1674
 - for rotavirus, 1126

- for *Toxoplasma gondii*, e1
- for *Tropheryma whippelii*, 457
- Positron emission tomography, in fever of unknown origin, 191
- Postherpetic neuralgia
 - in elderly persons, 1481
 - after stem cell transplantation, 1414
- Practice guidelines (see Guidelines)
- Praziquantel
 - for hydatidosis, thigh muscle, e65
 - for *Schistosoma mansoni* infections, 1347, 1371
- Prednisolone, in T lymphocyte type 1/type 2 immunity, 76
- Prednisone, for herpes zoster, 1481
- Pregnancy
 - brucellosis in, 1172
 - HIV infection in, iron status and, 1496
 - TT virus carriage in, 1376
- Prion infections
 - clinical implications, 1726
 - disinfection and sterilization for, 1348
- Probenecid, for syphilis, in HIV infection, 611
- Probiotics
 - Enterococcus faecium*, 1381
 - modern perspective, 1567, 1577
 - vaginal flora and, e69
- Procalcitonin, for infection detection, in neutropenia, 1718
- Proctitis
 - due to herpes simplex virus, in HIV infection, 611
 - due to *Neisseria gonorrhoeae*, in HIV infection, 611
- Progestins, in T lymphocyte type 1/type 2 immunity, 76
- Progressive multifocal leukoencephalopathy, treatment, failure, 150
- Pronase, inactivated, in cryptococcal antigen test kit, 836
- Prophylaxis (see also Infection control)
 - Campylobacter jejuni* infections, safe food handling practices in, 1201
 - Creutzfeldt-Jacob disease, 1348
 - cytomegalovirus infections, 596
 - in HIV infection, 783
 - in transplantation, 742
 - fungal infections, in intensive care unit, 1191
 - histoplasmosis, in HIV infection, 1215
 - HIV infection, postexposure, 1494
 - mycobacterial infections, in cystic fibrosis, 1298
 - Mycobacterium avium* complex infections, in HIV infection, 1615
 - opportunistic infections, in HIV infection, 116
 - sexually transmitted diseases, in travelers, 1063
 - streptococci group B, in neonates, Current News, May 15
 - tickborne diseases, 897
- Prosthetic joint infections
 - hip, treatment, 419
 - due to *Staphylococcus aureus*, 647
- Prosthetic valve infections, due to *Staphylococcus hemolyticus*, e100
- Protein C, for meningococcemia, 1338
- Proteus mirabilis*, resistance in, global, S94
- Protozoan infections, pathology, 1589
- Pseudomonas aeruginosa* infections
 - catheter-related, guidelines, 1249
 - pathology, 1589
 - resistance in
 - fluoroquinolones, 162
 - global, S146, S156
 - trimethoprim-sulfamethoxazole, 1608
- Public health (see also Bioterrorism)
 - blastomycosis response, e151
 - clinical microbiology laboratory services and, 604, 605
 - infectious diarrhea, 331
 - vaccine role in, 283
- Purpura
 - in *Neisseria meningitidis* infections, in pediatric patients, 1004
 - thrombotic thrombocytopenic, syndrome resembling, in parvovirus B19 infections, 311
- Purpura fulminans, due to *Neisseria meningitidis*, protein C replacement in, 1338
- Pyelonephritis, due to *Candida*, 1602
- Pyuria, due to *Candida*, 1602
- Q fever
 - myocarditis in, 1440
 - nosocomial, prevention, 446
 - review, 897
- Quality of life, in HIV infection, measurement, e47
- Quinine
 - for babesiosis, 1117
 - blackwater fever due to, 1133
- Quinolones (see also Fluoroquinolones; specific drug)
 - mechanism of action of, S9
 - resistance to, cross-resistance and dichotomous, S1
- Quinupristin-dalfopristin
 - for intravascular catheter-related infections, 1249
 - resistance in, *Enterococcus*, S133
 - side effects, e83
- Rabies, nosocomial, prevention, 446
- Rash
 - due to herpes zoster, 1414, 1481
 - due to nevirapine, 124
 - due to *Staphylococcus aureus*, 1470
- Rectal infections (see Anorectal infections)
- Red cell aplasia, in HIV infection, highly active antiretroviral therapy effects on, in pediatric patients, 464
- Rehabilitation, institutions for, methicillin-resistant *Staphylococcus aureus* carriage in, 1393
- Relapsing fever, review, 897
- Research, fellowship training on, adequacy of, 255
- Residency programs, in infectious disease, 752, 755
- Resistance, drug (see Drug resistance)
- Respiratory failure, in babesiosis, 1117
- Respiratory infections (see also Pneumonia; Tuberculosis)
 - due to adenovirus
 - in bone marrow transplantation, 871
 - in Korean children, 1423
 - type 7d2, outbreaks, 694
 - due to *Aspergillus*
 - in bone marrow transplantation, 1319
 - mortality in, 358
 - due to *Burkholderia pseudomallei*, in cystic fibrosis, e15
 - due to *Coccidioides immitis*, risk factors for, 708
 - due to *Cryptococcus neoformans*, in cancer, e145
 - due to *Enterococcus*, resistance in, S133
 - in Good's syndrome [letter], 323
 - due to *Haemophilus influenzae*, resistance in, S81
 - in HIV infection, due to *Pneumocystis carinii* and tuberculosis, 289
 - due to human papillomavirus, treatment with cidofovir, e62
 - due to *Moraxella catarrhalis*, resistance in, S81
 - due to *Mycobacterium avium* complex, treatment, 1547
 - due to *Paragonimus westermani*, clinical features, e171
 - due to *Pneumocystis carinii*
 - detection in immunocompetent infants, 855
 - in HIV infection, 289
 - due to *Pseudomonas aeruginosa*, resistance in, S146
 - due to *Rhodococcus equi*, e39
 - due to *Streptococcus pneumoniae*, resistance in, S81
 - treatment
 - fluoroquinolones, S64

- moxifloxacin for, S51
- Restriction endonuclease analysis, for microorganisms in global resistance surveillance program, S156
- Restriction fragment-length polymorphism analysis, for microorganisms in global resistance surveillance program, S156
- Retinitis
- due to *Candida*, in neonates, 1018
 - due to cytomegalovirus
 - in HIV infection, 815, Current News, May 1
 - after stem cell transplantation, 214 - due to *Treponema pallidum*, 1661
- Retrocalcaneal bursitis, septic, in pediatric patients, e102
- Rhabdomyolysis, in HIV infection, 502
- Rheumatoid arthritis, juvenile, *Bartonella* infections in, e22
- Rheumatoid nodule, pathology, 1589
- Rhinocerebral zygomycosis, treatment with granulocyte-macrophage colony-stimulating factor, e166
- Rhipicephalus* species, review, 897
- Rhodococcus equi* infections
- diagnosis, 929, 970
 - in immunocompetency, e39
- Ribavirin
- for adenovirus infections
 - in bone marrow transplantation, 871
 - in stem cell transplantation, 1290 - for parainfluenza virus infections, after stem cell transplantation, 413
- Rickettsia* infections, review, 897
- Rickettsia prowazekii* infections, meningitis, 979
- Rifabutin
- for *Mycobacterium avium* complex infections, 1547
 - prophylactic, in HIV infection, 1615
 - for tuberculosis [letters and reply], 321-323
- Rifampin
- for brucellosis, in pregnancy, 1172
 - for leprosy, 930
 - for *Mycobacterium avium* complex infections, 1547
 - resistance to
 - Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114 - for *Staphylococcus aureus* infections, vancomycin-resistant, 108
 - for tuberculosis, in HIV infection, 623
- Risk factors, meningococcal infections, invasive, in school workers, 1795
- Ritonavir, for HIV infection
- ototoxicity, 1623
 - resistance to, monitoring, 774
- The River: A Journey to the Source of HIV and AIDS*, on HIV transmission, 1068
- RNA
- HIV, non-B subtype, polymerase chain reaction in, 1227
 - synthesis, fluoroquinolone effects on, S9
- Rocky Mountain spotted fever, review, 897
- Rotavirus infections, severity, vs. viral strain, 1126
- Round pneumonia, due to *Streptococcus pneumoniae*, 1188, 1233
- Safety, of vaccines, 283
- Salmonella enteritidis* infections, phage type 4, 890
- Salmonella* infections
- bacteremia, emergency room management, 559
 - diarrhea
 - epidemiology, 573
 - practice guidelines, 331 - extraintestinal, *spv* genes in [letter and reply], 519
 - nontyphoidal, review, 263
 - resistance in
 - global, S94
 - nontyphoidal, 263
 - trimethoprim-sulfamethoxazole, 1608
- Salmonella typhimurium* infections, T lymphocyte type 1/type 2 immunity in, 76
- Salpingitis, treatment, Centers for Disease Control and Prevention guidelines, 103
- Sandfly fever virus encephalitis, serotype Toscana, without meningitis, 1241
- Saquinavir, resistance to, monitoring, 774
- Sarcoidosis, Kaposi's sarcoma with, virus detection in, 1100
- Sarcoma, Kaposi's, sarcoidosis with, virus detection in, 1100
- Scedosporium apiospermum* infections, lymphadenitis in, e59
- Scedosporium prolificans* infections, disseminated, e158
- Schistosoma japonicum* infections, pathology, 1589
- Schistosoma mansoni* infections, brain, 1347, 1371
- Schizophrenia, toxoplasmosis in, 842
- Scintigraphy, gallium, in fever of unknown origin, 191
- Scrapie, mad cow disease and, 1726
- Seizures
- in enterovirus 71 infections, 236
 - in *Mycoplasma pneumoniae* infections, e31
 - in toxoplasmosis, e1
- SENTRY Antimicrobial Surveillance Program
- Acinetobacter*, S104, S156
 - Enterobacteriaceae, S156
 - Enterococcus*, S133, S156
 - Escherichia coli*, S94, S156
 - extended-spectrum β -lactamase-producing organisms, S94, S156
 - gram-negative bacteria, S156
 - Haemophilus influenzae*, S81
 - Klebsiella pneumoniae*, S94, S156
 - molecular characterization integration in, S94, S156
 - Moraxella catarrhalis*, S81
 - Proteus mirabilis*, S94
 - Pseudomonas aeruginosa*, S146, S156
 - Salmonella*, S94
 - Staphylococcus*, S114
 - Staphylococcus aureus*, methicillin-resistant, S156
 - Stenotrophomonas maltophilia*, S104, S156
 - Streptococcus pneumoniae*, S81, S156
- Sepsis
- due to *Bacillus cereus*, in immunodeficiency, in pediatric patients, 1456
 - after bee sting, due to *Streptococcus pyogenes*, e36
 - due to *Campylobacter jejuni*, in pediatric patients, e97
 - due to *Chromobacterium violaceum*, in pediatric patients, e107
 - due to *Neisseria meningitidis*, protein C replacement in, 1338
 - neonatal, due to gram-negative organisms, Current News, May 15
 - in panhypopituitarism, 153
- Septic arthritis (see Arthritis, septic)
- Septic bursitis, in pediatric patients, e102
- Septic shock, due to *Neisseria gonorrhoeae*, e92
- Serratia marcescens* infections
- catheter-related, guidelines, 1249
 - resistance in
 - fluoroquinolones, 162
 - trimethoprim-sulfamethoxazole, 1608
- Severe combined immunodeficiency, enterovirus infections in, treatment with pleconaril, e13
- Sex differences
- in fellowship training survey response, 255
 - in nevirapine rash, 124
- Sexually transmitted diseases (see also specific diseases)
- in HIV infection, 611
 - screening for, 808
 - in travelers, 1063
- Shiga toxin, *Escherichia coli*
- diarrhea, epidemiology, 573
 - testing for [letter], 1517

- Shigella* infections
 diarrhea
 epidemiology, 573
 practice guidelines, 331
 resistance in, trimethoprim-sulfamethoxazole, 1608
- Shingles
 in elderly persons, 1481
 after stem cell transplantation, 1414
- Shock (see also Toxic shock syndrome)
 in dengue hemorrhagic fever
 microvascular leakage in, noninvasive measurement, 243
 treatment, 204
 due to *Neisseria gonorrhoeae*, e92
- Sickle cell disease, *Streptococcus pneumoniae* infections in, in pediatric patients, 1155
- Simian immunodeficiency virus, in poliovirus vaccine, HIV transmission hypothesis, 1068
- Sinuses, surgery on, chemical meningitis after, vs. bacterial meningitis, 179
- Sinusitis
 in HIV infection, *Mycobacterium avium* complex prophylaxis and, 1615
 due to *Streptococcus pneumoniae*, treatment, S22
 treatment, S51, S64
- Skin grafts, for chronic venous disease, 949
- Skin lesions
 due to *Alternaria*, in diabetes mellitus, 1178
 due to *Aspergillus*, mortality in, 358
 due to *Brucella* endocarditis, 63, 149
 due to *Candida*, 1579, 1637
 due to *Chromobacterium violaceum*, in pediatric patients, e107
 due to drug reaction, skip areas in, e17
 due to fluoroquinolones, S72
 due to *Fusarium*, in heart-liver transplantation, 1237
 due to herpes simplex virus, 1480, 1500
 in HIV infection, 611
 due to herpes zoster, 1481
 in HIV infection, 611, 1615, 1628
 due to human papillomavirus, in HIV infection, 611
 due to *Leishmania*, *braziliensis* vs. *guyanensis*, 1304
 due to *Mycobacterium leprae*, 930
 due to nevirapine, 124
 due to *Staphylococcus*, S114
 due to *Staphylococcus aureus*
 intracellular persistence, 1643
 in toxic shock syndrome, 1470
 in syphilis, in HIV infection, 611
 due to tickborne pathogens, 897
- Skin tests
 for penicillin allergy, 317
 guidelines, 1685
 tuberculin, for hospital physicians, epidemiology, 1331
- Skull, osteitis, due to *Treponema pallidum*, in HIV infection, 667
- Smoking, coccidioidomycosis risk in, 708
- Soap, antimicrobial, for hand cleansing, artificial fingernail colonization and, 367
- Social responsibility, vaccine role in, 283
- Socioeconomic factors, in *Helicobacter pylori* infection epidemiology, 1387
- Soft-tissue infections
 in HIV infection, *Mycobacterium avium* complex prophylaxis and, 1615
 due to *Staphylococcus*, resistance in, S114
- Solid-organ transplantation (see Transplantation, solid-organ; specific organs)
- Sparfloxacin
 mechanisms of action, S9
 pharmacodynamics, S39
 resistance to, S1
 toxicity, S72
- Spider bites, vs. infections, 595, 636
- Spinal cord (see also Myelitis; Myelopathy)
 infections, book reviews, 1244
 medullary gnathostomiasis, e154
- Spine
 epidural abscess, in pediatric patients, 9
 epidural lipomatosis, due to corticosteroids, e90
 osteomyelitis
 due to *Candida*, 527
 due to nontuberculous mycobacteria, 1506
 in pediatric patients, 9
 surgery on
 Candida infections after, 352
 chemical meningitis after, vs. bacterial meningitis, 179
- Spleen
 abscess, due to *Brucella*, 1024
 disorders, due to *Campylobacter fetus*, in HIV infection, 295
 Sporotrichoid lymphangitis, due to *Streptococcus* group A, e176
 Sporotrichosis, pathology, 1589
- Sputum, *Mycobacterium tuberculosis* persistence in, inhaled aminoglycosides for, 44
- spv* genes, in *Salmonella* infections, extraintestinal [letter and reply], 519
- Stains, tissue, for infection diagnosis, 1589
- Staphylococcus aureus*
 on artificial nails, hand cleansing effects on, 367
 in vaginal flora, e69
- Staphylococcus aureus* infections
 bacteremia, venous port-related, 1776
 catheter-related, guidelines, 1249
 diabetic ketoacidosis in, 30
 mediastinitis, methicillin resistance and, 877
 methicillin-resistant
 colonization
 after hospital discharge, 1393
 viridans streptococci effects on, in newborns, 1399, 1408
 global status, S114, S156
 mediastinitis, 877
 outbreaks, Switzerland, 581
 pneumonia, treatment, 402
 pathology, 1589
 pneumonia
 lung tap for, 715
 methicillin-resistant (see *Staphylococcus aureus* infections, methicillin-resistant)
 prosthetic joints, 647
 resistance in
 quinolones, S1
 teicoplanin, 108
 trimethoprim-sulfamethoxazole, 1608
 vancomycin, 108
 small-colony variant, intracellular persistence, 1643
 spinal epidural abscess, in pediatric patients, 9
 toxic shock syndrome in, 1470
 nonmenstrual, e53
 treatment, fluoroquinolones, S33
- Staphylococcus epidermidis*, in vaginal flora, e69
- Staphylococcus epidermidis* infections
 bacteremia, venous port-related, 1776
 catheter-related, guidelines, 1249
 treatment, fluoroquinolones, S33
- Staphylococcus hemolyticus* infections, prosthetic valve endocarditis, e100
- Staphylococcus* infections
 coagulase-negative
 bacteremia, venous port-related, 1776

- resistance in, global, S114
 - hip arthroplasty, treatment, 419
 - resistance in, global, S114
- Stavudine, for HIV infection
 - ototoxicity, 1623
 - resistance to, monitoring, 774
- Stem cell transplantation
 - adenovirus infections in, 871, 1290
 - in breast cancer, infections after, 546
 - cytomegalovirus retinitis in, 214
 - infectious complications, after 1 year, 391
 - parainfluenza virus infections in, treatment, 413
 - toxoplasmosis in, e1
 - varicella-zoster virus infections in, predictive model for, 1414
- Stenotrophomonas maltophilia* infections
 - bacteremia, venous port-related, 1776
 - catheter-related, guidelines, 1249
 - resistance in, global, S104, S156
 - susceptibility testing [letter], 1656
- Sterilization, Creutzfeldt-Jacob disease prevention, 1348
- Stenotomy, mediastinitis after, due to *Staphylococcus aureus*, methicillin resistance and, 877
- Still's disease, due to *Mycoplasma pneumoniae*, e105
- Stings, insect, fatal infections after, e36
- Stomach, aspirate from, in tuberculosis diagnosis, 17
- Stool culture, in diarrhea, 331
- Streptococcal infections
 - group A
 - antibody dynamics in, e24
 - pharyngitis, treatment, 1798
 - resistance in, trimethoprim-sulfamethoxazole, 1608
 - retrocalcaneal bursitis, e102
 - sepsis, after bee sting, e36
 - sporotrichoid lymphangitis, e176
 - treatment, moxifloxacin, S30
 - group B
 - prophylaxis, in neonates, Current News, May 15
 - spinal epidural abscess, in pediatric patients, 9
 - β -hemolytic, laboratory tests for, e9
 - hip arthroplasty, treatment, 419
 - T lymphocyte type 1/type 2 immunity in, 76
- Streptococci
 - group B, in normal vaginal flora, e69
 - viridans, in methicillin-resistant *Staphylococcus aureus* colonization inhibition, in neonates, 1399, 1408
- Streptococcus anginosus* infections, abscess, 1511
- Streptococcus constellatus* infections, abscess, 1511
- Streptococcus intermedius* infections
 - abscess, 1511
 - hepatopulmonary syndrome in, e131
- Streptococcus milleri* group infections, abscess, 1511
- Streptococcus pneumoniae*
 - colonization
 - antibiotic-resistant, in Asian children, 1463
 - in pediatric patients, Indonesia, 1039
 - in vaginal flora, e69
 - vancomycin tolerance, 552
- Streptococcus pneumoniae* infections
 - bacteremia, emergency room management, 559
 - diagnosis, pneumolysin antibody detection in, 534
 - epidemiology, in pediatric patients, in Africa, 64
 - in HIV infection, 794
 - meningitis, fever interval in, in pediatric patients, 566
 - pneumonia
 - in Finland, 1141
 - lung tap for, 715
 - round mass in, 1188, 1233
 - resistance in, 1039
 - fluoroquinolones, S39
 - global, S81, S156
 - levofloxacin, 701
 - multiple, 1463
 - penicillin, S22, 972, 1044
 - quinolones, S1
 - vancomycin, 552
 - treatment
 - fluoroquinolones, S39
 - moxifloxacin, S22, S51, S64
 - urinary assay for, in pediatric patients, 824
 - vaccination
 - in heart transplantation, 307
 - in HIV infection, 794
- Streptococcus pyogenes* infections (see Streptococcal infections, group A)
- Streptomycin
 - for *Mycobacterium avium* complex infections, 1547
 - resistance to, *Enterococcus*, S133
 - for Whipple's disease, 457
- Stroke, in HIV infection, 1487
- Strongyloides stercoralis* infections, pathology, 1589
- Subacute sclerosing panencephalitis, in American-born adult, 173
- Sulfadiazine, for toxoplasmosis, e1
- Sulfamethoxazole, resistance to, *Streptococcus pneumoniae*, 1039
- Sulfonamides, resistance to, 1608
- Surgery
 - for chronic venous disease, 949
 - for human papillomavirus infections, 611
 - for osteomyelitis, due to *Candida*, 527
- Surgical infections
 - due to *Candida*, 352
 - meningitis, after neurological surgery, 179
 - due to *Staphylococcus aureus*, methicillin resistance and, 877
- Surveillance (see also SENTRY Antimicrobial Surveillance Program), *Haemophilus influenzae*, after vaccination, 2
- Susceptibility testing (see also Drug resistance)
 - Abiotrophia*, e140
 - moxifloxacin, *Streptococcus pyogenes*, S30
- Sydenham, Sir Thomas, on prudent skepticism [letter], 1519
- Syphilis
 - in HIV infection, 611
 - osteitis in, 667
 - neurologic, vs. herpes simplex virus encephalitis, 1108
 - pathology, 1589
 - uveitis in, 1661
- Teicoplanin, resistance to, *Staphylococcus aureus*, 108
- Temafloxacin, toxicity, S72
- Tendonitis, fluoroquinolone-induced, S72
- Terrorism (see Bioterrorism)
- Testosterone
 - in T lymphocyte type 1/type 2 immunity, 76
 - for wasting, in HIV infection, 116
- Tetracycline(s)
 - for cholera, 331
 - for ehrlichiosis, 897
 - resistance to, 1162
 - Acinetobacter*, S104
 - extended-spectrum β -lactamase-producing organisms, S94
 - Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114
 - Stenotrophomonas maltophilia*, S104
 - Streptococcus pneumoniae*, S81
- Thalidomide

- for HIV infection, 1738
- for leprosy, 930
- Thrombocytopenia
 - in babesiosis, 1117
 - in ehrlichiosis, 862
 - in parvovirus B19 infections, 311
- Thrombosis
 - in cytomegalovirus infections, 983
 - septic, catheter-related, 1249
- Thrombotic thrombocytopenic purpura, syndrome resembling, in parvovirus B19 infections, 311
- Thrush, in HIV infection, 1554
- Thymoma, in Good's syndrome, adult-onset [letter], 323
- Thyroxine replacement, HIV prophylactic drug interactions with, 1635
- Ticarcillin
 - for intravascular catheter-related infections, 1249
 - resistance to, *Acinetobacter*, S104
- Ticarcillin-clavulanate, resistance to
 - Acinetobacter*, S104
 - Stenotrophomonas maltophilia*, S104
- Ticks, diseases transmitted by (see also Ehrlichiosis; Lyme disease)
 - as nonspecific fever cause, 1434
 - review, 897
 - tick paralysis, 897
- T lymphocytes
 - CD4
 - in HIV infection, 1738, 1756
 - in stem cell transplantation, varicella-zoster virus infection and, 1414
 - types, 76
 - CD8
 - in HIV infection, 1738, 1756
 - in stem cell transplantation, varicella-zoster virus infection and, 1414
 - deficiency, liver abscess in, due to *Fusobacterium nucleatum* [letter], 326
 - helper, types, 76
 - in HIV infection, 1756
 - immune-related therapy and, 1738
 - vs. iron status, 1496
 - type 1/type 2 immunity in, 76
 - in virologic rebound, 1231
 - type 1/type 2 immunity, 76
- Tobramycin
 - area under inhibitory concentration curve values, S39
 - for intravascular catheter-related infections, 1249
 - resistance to, 1162
 - Acinetobacter*, S104
 - extended spectrum β -lactamase-producing organisms, S94
 - Pseudomonas aeruginosa*, S146
 - Stenotrophomonas maltophilia*, S104
- Toe(s), acrodermatitis continua of Hallopeau, 431, 505
- Toenail disorders, due to indinavir, 140
- Tolerance, vancomycin, in *Streptococcus pneumoniae*, 552
- Tonsillitis, due to *Staphylococcus aureus*, methicillin-resistant, in injection drug users, 581
- TOPOFF exercise, for bioterrorism preparation, 436
- Topoisomerase inhibition, fluoroquinolones in, S9
- Tosufloxacin, resistance to, S1
- Toxic shock syndrome, nonmenstrual
 - recurrent, 1470
 - due to staphylococci, e53
- Toxocariasis, as asthma risk factor, e111
- Toxoplasmosis
 - in schizophrenia, 842
 - in stem cell transplantation, e1
- Tracheobronchitis, due to adenovirus, in Korean children, 1423
- Transferrin receptor, as HIV severity marker, 1496
- Transfusions
 - cytomegalovirus transmission in, prevention, 596
 - as *Streptococcus pneumoniae* infection risk, in HIV infection, 794
- Transmissible spongiform encephalopathy, prevention, disinfection and sterilization for, 1348
- Transplantation
 - Aspergillus* infections in, mortality in, 358
 - bone marrow
 - adenovirus infections in, 871, 1325
 - aspergillosis in, e94
 - Candida lusitanae* infections in, 186
 - hemorrhagic cystitis in, 1325
 - infectious complications, after 1 year, 391
 - invasive fungal infections in, 1319
 - cytomegalovirus infections in
 - preemptive treatment vs. prophylaxis, 742
 - prevention, 596
 - heart, pneumococcal vaccination in, 307
 - heart-liver, *Fusarium* infections in, 1237
 - kidney
 - genitourinary tuberculosis after, 662
 - human herpesvirus 6 and 7 infections in, 1357
 - human herpesvirus 8 detection, Kaposi's sarcoma development, 1502
 - liver
 - cytomegalovirus infections in, 742
 - hepatitis A vaccination in [letter], 1656
 - human herpesvirus 6 and 7 infections in, 1357
 - pancreas, human herpesvirus 6 and 7 infections in, 1357
 - solid-organ (see also specific organs)
 - stem cell
 - adenovirus infections in, 871, 1290
 - in breast cancer, infections after, 546
 - cytomegalovirus retinitis after, 214
 - infectious complications, after 1 year, 391
 - parainfluenza virus infections after, treatment, 413
 - toxoplasmosis in, e1
 - varicella-zoster virus infections after, predictive model for, 1414
- Transverse myelitis, in enterovirus 71 infections, 236
- TRAVAX database, for travel medicine information, 757
- Traveler's diseases (see also Malaria)
 - due to *Burkholderia pseudomallei*, in cystic fibrosis, e15
 - diarrhea, practice guidelines, 331
 - due to enteroaggregative *Escherichia coli*, 1706, 1710
 - HIV type 1 non-B subtype, 1732
 - information resources for, 757
 - sexually transmitted, 1063
- Treponema pallidum* infections (see Syphilis)
- Treponemal tests, for syphilis, in HIV infection, 611
- Trichinosis
 - T lymphocyte type 1/type 2 immunity in, 76
 - treatment, failure, 638
- Trichloroacetic acid, for human papillomavirus infections, 611
- Trichomoniasis
 - in HIV infection, 611
 - screening for, 808
 - pathology, 1589
- Trichophyton beigelii* infections, catheter-related, guidelines, 1249
- Trichuriasis, T lymphocyte type 1/type 2 immunity in, 76
- Trimethoprim-sulfamethoxazole
 - for brucellosis, in pregnancy, 1172
 - for *Chromobacterium violaceum* sepsis, e107
 - for diarrhea, 331
 - for intravascular catheter-related infections, 1249

- for melioidosis, in cystic fibrosis, e15
- prophylactic
 - for histoplasmosis, in HIV infection, 1215
 - for *Mycobacterium avium* complex infections, in HIV infection, 1615
- resistance to, 1162, 1608
 - Enterococcus*, S133
 - extended-spectrum β -lactamase-producing organisms, S94
 - Haemophilus influenzae*, S81
 - Staphylococcus*, coagulase-negative, S114
 - Staphylococcus aureus*, S114
 - Streptococcus pneumoniae*, S81
 - for *Staphylococcus aureus* infections, vancomycin-resistant, 108
 - for Whipple's disease, 457
- Tropheryma whippelii* infections, recent developments concerning, 457
- Tropical spastic paraparesis, inclusion body myositis in, 510
- Trovafoxacin
 - for endocarditis, due to *Streptococcus pneumoniae*, 972
 - pharmacodynamics, S39
 - resistance to, S1
 - Acinetobacter*, S104
 - Pseudomonas aeruginosa*, S146
 - Stenotrophomonas maltophilia*, S104
 - toxicity, S72
- TT virus, colonization, in pregnancy, 1376
- Tuberculin test, for hospital physicians, epidemiology, 1331
- Tuberculosis
 - diagnosis, in pediatric patients, 17
 - epidemiology, Internet resources on, 1580
 - genitourinary, in transplantation, 662
 - in HIV infection
 - chemokine receptor expression in, 650
 - multidrug-resistant, 159
 - Pneumocystis carinii* infection with, 289
 - recurrence, 515
 - in Thailand, 955
 - treatment, 623
 - information resources for, on Internet, 1580
 - lymphadenitis in, vs. *Scedosporium apiospermum* infection, e59
 - meningitis in, treatment, 643
 - multidrug-resistant, 159
 - nosocomial, due to *Mycobacterium bovis* strain B, 159
 - pathology, 1589
 - recurrence, in HIV infection, 515
 - regulations on, Internet resources on, 1580
 - research on, Internet resources on, 1580
 - resistance in, multiple, clinical outcome, 373
 - T lymphocyte type 1/type 2 immunity in, 76
 - treatment, 373
 - refractory, inhaled aminoglycosides in, 44
 - treatment [letters and reply], 321-323
- Tubo-ovarian abscess, treatment, Centers for Disease Control and Prevention guidelines, 103
- Tularemia, review, 897
- Tumor(s), fever in, imaging studies, 191
- Typhus, epidemic, meningitis in, 979
- Ulcer(s)
 - cutaneous, due to *Alternaria*, in diabetes mellitus, 1178
 - venous, treatment, 949
- Unna boot, for chronic venous disease, 949
- Urea breath test, for *Helicobacter pylori*, breast-feeding practices and, 1387
- Ureaplasma urealyticum* infections
 - in HIV infection, 611
 - urethritis, 995
- Urethritis
 - due to herpes simplex virus, 611
 - in HIV infection, 611
 - due to *Mycoplasma genitalium*, 995
 - due to *Neisseria gonorrhoeae*, 611
 - due to *Ureaplasma urealyticum*, 995
- Urinary tract infections
 - due to adenovirus, 871
 - in bone marrow or stem cell transplantation, 391, 871
 - due to *Candida*, nosocomial, 1602
 - diabetic ketoacidosis in, 30
 - due to *Enterococcus*, resistance in, S133
 - due to *Escherichia coli*, virulence factors, 1523
 - due to *Mycobacterium tuberculosis*, after kidney transplantation, 662
 - in panhypopituitarism, 153
 - due to *Staphylococcus*, resistance in, S114
- Urine, Shiga toxin testing [letter], 1517
- Urticaria, meningococcal vaccines, 1273
- Uveitis, due to *Treponema pallidum*, 1661
- Vaccine Adverse Event Reporting System, meningococcal polysaccharide vaccine data from, 1273
- Vaccines and vaccination
 - future of, 675
 - Haemophilus influenzae*
 - antibody measurement after, 2
 - failure, 1700
 - hepatitis A
 - boosters, 396
 - in liver transplantation [letter], 1656
 - hepatitis B
 - in injection drug users, e143
 - in travelers, 1063
 - HIV infection, in neonates, 801
 - infectious diarrhea, 331
 - influenza
 - in HIV infection, 1784
 - measles, in HIV infection, highly active antiretroviral therapy effects on, 1090
 - meningococcal, intramuscular vs. subcutaneous, 170
 - Neisseria meningitidis*, safety data, 1273
 - pneumococci, in heart transplantation, 307
 - poliomyelitis, HIV transmission hypothesis, 1068
 - public health aspects of, potential of, 283
 - safety, 283
 - sexually transmitted diseases, 1063
 - Streptococcus pneumoniae*, in HIV infection, 794
 - therapeutic, for HIV infection, 1738, 1756
 - T lymphocyte type 1/type 2 immunity and, 76
 - varicella-zoster virus, for herpes zoster prevention, 1481
- Vagina
 - microbicides for, safety, 476
 - microflora
 - normal, e69
 - variation during menstrual cycle [letter], 325
- Vaginitis
 - after bone marrow or stem cell transplantation, 546
 - due to *Candida*, treatment with probiotics, 1567
- Valacyclovir
 - for herpes simplex virus, in HIV infection, 611
 - for herpes zoster, 1481
- Valganciclovir, for cytomegalovirus infections, Current News, May 1
 - in HIV infection, 783
- Valvular heart disease, fungal endocarditis in, 50
- Vancomycin
 - for endocarditis, due to *Streptococcus pneumoniae*, 972

- for intravascular catheter-related infections, 1249
- for pneumonia, nosocomial, 402
- resistance to
 - enterococci, 1373
 - bacteremia outcome [letter and reply], 1110, 1112
 - coresistance patterns, S133
 - endocarditis, 1373
 - in hemodialysis, 23
 - Enterococcus faecium*, 1381
 - Moraxella catarrhalis*, S81
 - Staphylococcus aureus*, 108
 - Streptococcus pneumoniae*, 552
- tolerance, in *Streptococcus pneumoniae*, 552
- Varicella-zoster virus infections (*see also* Herpes zoster)
 - after autologous peripheral blood progenitor cell transplantation, predictive model for, 1414
 - pathology, 1589
- Vasculitis
 - fever in, imaging studies, 191
 - in HIV infection, 1628
- Venous disease, chronic, treatment, 949
- Venous thrombosis, in cytomegalovirus infections, 983
- Vertebrae (*see* Spine)
- Vibrio cholerae* infections, practice guidelines, 331
- Vibrio cholerae* non-serogroup O:1 infections, case studies, e117
- Vidarabine, for adenovirus infections, in stem cell transplantation, 1290
- Viral infections, pneumonia, lung tap for, 715
- Viridans streptococci, in methicillin-resistant *Staphylococcus aureus* colonization inhibition, in neonates, 1399, 1408
- Virulence factors, *Escherichia coli*, in urinary tract infections, 1523
- Visceral leishmaniasis
 - in HIV infection, highly active antiretroviral therapy effects on, 633
 - without endemic area exposure, 302
- Vision disorders, in *Mycoplasma pneumoniae* infections, e31
- Warts, genital, due to human papillomavirus, in HIV infection, 611
- Wasting, in HIV infection, 955
 - antibiotic prophylaxis in, 116
 - death from, 1487
- Web (*see* Internet resources)
- Weight management, in HIV infection, 1769
- Western blot test
 - for *Gnathostoma spinigerum*, e154
 - for *Toxoplasma gondii*, in schizophrenia, 842
- West Nile virus encephalitis
 - outbreaks, New York City, 277
 - reemergence, 675
- Whipple's disease, as emerging infection, 457
- Wound infections
 - due to *Edwardsiella tarda*, 1430
 - due to *Enterococcus*, resistance in, S133
- Yersinia* infections, diarrhea, practice guidelines, 331
- Yersinia pestis* infections
 - nosocomial, prevention, 446
 - in simulated bioterrorist attack, drill for, 436
- Zalcitabine, for HIV infection, resistance to, monitoring, 774
- Zidovudine, for HIV infection
 - prophylactic, 1494
 - resistance to, monitoring, 774
- Ziehl-Neelsen stain, for infection diagnosis, 1589
- Zinc lozenges, for colds, additive effects on [letter], 1520
- Zoonoses (*see also* specific diseases)
 - nosocomial, review, 446
 - tickborne, review, 897
- Zygomycosis
 - pathology, 1589
 - rhinocerebral, treatment with granulocyte-macrophage colony-stimulating factor, e166